Systematic review

Colorectal cancer and microbiota modulation for clinical use. A systematic review.

Julio Madrigal-Matute^{*} and Sara Bañón Escandell Biomedical Institute for Nutrition and Health (IBIONS).

*Corresponding author: **Julio Madrigal-Matute, PhD** *Biomedical Institute for Nutrition and Health (IBIONS).* Phone: +34606008917; <u>Madrigal-matute@ibions.com</u>

Abstract

Colorectal cancer is one of the top contributors to the global burden of cancer incidence and mortality with genetic and environmental factors contributing to its etiology. Modifiable or environmental factors can be the cause of up to 60% of the risk of developing colorectal cancer. Hence, there is a growing interest in specifically defining what can be improved in our lifestyle to reduce this risk, improve the effectiveness of treatments, reduce side effects, and decrease the risk of recurrence. One of the elements directly related to lifestyle is gut microbiota. The microbial ecosystem has a vital role in colorectal cancer prevention and antitumoral response through modulation of the immune system and production of short-chain fatty acids. Numerous approaches have been used to identify healthy microbiota that can reduce the risk of cancer development, improve treatment efficacy, and reduce side effects.

Scientific literature in this subject is growing exponentially and, therefore, systematic reviews and meta-analysis are required to ensure that appropriate recommendations are given to patients.

This work aimed to perform a systematic analysis of the published literature to elucidate whether microbiota modulation through pre-, pro-, symbiotic treatment and/or nutritional intervention can be beneficial for patients diagnosed with colorectal cancer.

Detailed analysis of published studies shows that some prebiotics, such as inulin and resistant starch, probiotics such as lactic strains producers of short-chain fatty acids, and consumption of unprocessed plant products, can be effective recommendations for patients diagnosed with colorectal cancer. This advice should always be individually tailored and followed up by a healthcare professional with expertise in the field.

Keywords: cancer, colorectal, nutrition, diet, probiotic, prebiotic, symbiotic, immunotherapy, immune system.

Abbreviations:

CRC, colorectal cancer; ROS, reactive oxygen species; RNS, reactive nitrogen species; MSI, Microsatellite instability; SCFA, Short chain fatty acids; LPS, Lipopolysaccharide; dMMR, deficient DNA mismatch repair; AOM, Azoxymethane; DSS, Dextran sodium sulfate; TNF- α , tumor necrosis factor alpha; MPO, Myeloperoxidase; PCNA, Proliferation cellular nuclear antigen; SLC5A8, Solute Carrier Family 5 Member 8; GPR43, G protein-coupled receptor 43; CEA, Carcinoembryonic antigen; APC, Adenomatous polyposis coli; DHM, 1.2-dimethyl hydrazine; TGF- β , Transforming growth factor beta; TLR2, toll-like receptor 2; DC, dendritic cells; PD-1, Programmed cell death protein 1; PDL-1, Programmed cell death protein ligand 1; CTLA-4, Cytotoxic T-Lymphocyte Associated Protein 4; CYP, Cytochrome P450 Family; GSTM1, Glutathione S-Transferase Mu 1; SULT1, Sulfotransferase Family-1; PYY, Peptide tyrosine; PPARy, peroxisome proliferator activated receptor gamma; 6,BR, 6-bromoisatin; NE, marine extract; MD, Mediterranean diet; LFD, low fat diet; HFD, high fat diet; EPA, Eicosapentanoic acid; PUFA, polyunsaturated fatty acids; CRP, C reactive protein; SFRP2, Secreted Frizzled Related Protein 2; DNMT1, DNA Methyltransferase 1; COX-2, Cyclooxygenase-2; PGE₂, Prostaglandin E2; Cxcl, C-X-C Motif Chemokine Ligand; BCL2 Interacting Killer; KC, Keratinocytes-derived chemokine; Gr-1, Bik, Glucocorticoid Receptor-1; CTNNB1, Beta catenin 1; EGFR, Epidermal growth factor receptor; TYMS, Thymidylate Synthetase; LPE, Lisophosphatidiletanolamine; LPC, Lisophosphatidylcholine; G-CSF, Granulocyte Colony-Stimulating Factor; GM-CSF, Granulocyte Macrophage Colony-Stimulating Factor; HDAC, Histone Deacetylase; JAM1, F11 Receptor; 5-FU, 5-florouracil; EGCG, epigallocatechin-3-gallate;

1

2 1. Introduction

3 **1.1. Colorectal cancer**

Colorectal cancer (CRC) is a disease based on an important genetic component, 4 coupled with key influence from our lifestyle habits. Approximately 10-20% of 5 diagnoses of CRC have a family history with the disease,¹ and through family and 6 twin studies, heritability is estimated to range from 12-35%.^{2, 3} Although numerous 7 8 genome-wide association studies have been performed identifying genes that increase susceptibility to develop CRC,⁴ many risk factors remain unknown. 9 However, only 5-7% of patients' colon cancer has a clear genetic origin.⁵ Hereditary 10 CRC syndromes can be subdivided into those associated with polyposis and those 11 without polyposis (Lynch syndrome and familial CRC).⁶ Risk factors also include the 12 development of inflammatory bowel disease, including Chron's disease and 13 ulcerative colitis. These pathologies significantly increase the chances of developing 14 CRC, being highly dependent on environmental and nutritional factors.⁷ Specifically, 15 geographical differences in incidence of CRC are influenced by genetic, and mainly 16 environmental and nutritional risks.⁸ 17

18 It is not surprising that environmental factors have such a strong influence on the 19 risk of developing colon cancer, as the intestinal epithelium is one of the tissues with 20 the highest turnover rate in our body and is in continuous direct contact with 21 nutrients, food toxins, and microbiota.⁹⁻¹⁴

22 Etiology

23 Among the metabolic changes that precede the development of cancer are chronic 24 cell damage due to a pathological increase in reactive oxygen and nitrogen species (ROS and RNS), DNA damage, and chronic inflammation.⁶ Inflammation triggers the 25 release of pro-inflammatory cytokines into the gut to regenerate damaged tissue. In 26 27 certain situations, inflammation becomes chronic, forming a positive feedback loop that facilitates tumor development.¹⁵ Colon tumors generally begin with the 28 transformation of stem and epithelial cells that reside at the base of the colonic 29 crypts. These cells undergo chronic damage by inflammation, oxidative stress, and/or 30 genetic mutations that evolve into a premalignant lesion or polyp.¹⁶ These polyps 31 follow two main routes of differentiation to malignancy: the adenoma-carcinoma type 32 (70-90%) and the serrated (10-20%) type. In addition, another route not associated 33

with polyposis has been described with a lower incidence, characterized by *microsatellite instability* (MSI; 2-7%).¹⁷ The development of a malignant tumor is estimated to take 10-15 years on average.⁶

37 **1.2. Gut microbiota**

The microbiome includes all types of microorganisms associated with the host, 38 interacting in a complex way and usually found in the epithelial barrier zones.¹⁸ It is 39 acquired at birth by vertical transmission and is modulated throughout our lives by 40 environmental factors.¹⁹ The microbiota is a dynamic niche that is involved in the 41 maintenance of health and in the origin and development of numerous diseases by 42 modulating the homeostasis of the immune system.²⁰ Although the mechanisms may 43 be varied, one of the most notably is the stimulation of the T-cell response, through 44 the expression of bacterial epitopes or their cross-reactivity with tumor epitopes. 45 Additionally, gut microbiota also modulates the response to tumors by inhibiting 46 specific receptors that promote inflammatory and immune responses. Finally, another 47 48 important mechanism carried out by the microbiota is the synthesis of metabolites, 49 such as short-chain fatty acids (SCFA), which elicit a local and systemic response in the host organism.¹⁹ 50

But what is the ideal microbiota composition for health? This is a question that is not 51 easy to answer, although numerous studies have attempted.^{21, 22} Analyzing a 52 metabolite panel comparing stool from healthy versus CRC patients, it was found that 53 54 the best marker to discern between a healthy patient and a CRC patient is primarily a decrease in the CRC patient's levels of certain SCFA, in particular, acetate and 55 butyrate.²³ The protective effect of SCFA against CRC may be due to their ability to 56 decrease inflammation and modulate the immune response.²⁴ In addition, SCFA 57 inhibit proliferation and promote apoptosis in neoplastic colonocytes.²⁵ 58

SCFA play a key role in maintaining intestinal health and preventing the 59 development of numerous pathologies.²⁶ They are produced by many bacteria in the 60 intestinal tract, in particular, lactic acid bacteria and bifidobacteria. SCFA transporters 61 62 and their receptors are the communication bridges between the microbiota and the cells of the gut.²⁷ Butyrate has been shown to decrease intestinal inflammation by 63 regulating epithelial occlusive junctions,²⁸ which are essential for maintaining the 64 65 integrity of the intestinal barrier and mucosa by aiding in the homeostasis of ions, nutrients and water.²⁹ 66

67 Among the SCFA-producing bacteria, and specifically butyrate, are those of the genus Butyricicoccus, which could protect against colitis in patients with irritable 68 bowel syndrome, as these bacteria are reduced in affected patients.³⁰ Likewise, other 69 bacteria belonging to the phylum Firmicutes such as Eubacterium rectale, 70 Ruminococcus albus, R. callidus, R. bromii and F. prausnitzii are 5 to 10 times more 71 abundant in healthy patients than in patients with Crohn's disease.³¹ The decrease in 72 species such as Bacteroides fragilis and B. vulgatus is associated with reduced 73 levels of butyric and propionic acid and increased inflammatory markers.³² 74 Additionally, Akkermansia muciniphila, one of the most abundant components of the 75 intestinal microbiota, is found to be decreased in obese patients.^{33, 34} those with 76 ulcerative colitis,³⁵ and those with CRC.³⁶ A. muciniphila ferments mainly mucins, as 77 well as other mono- and polysaccharides, giving rise to various SCFA.³⁷ 78

Taken together, it appears that SCFA-producing bacteria, such as acetate and
 butyrate are often associated with healthier microbiota profiles. For these reasons,
 SCFA are being tested as a therapy for CRC.³⁸

82 **Dysbiosis**

Pathological changes in the composition of the microbiota is known as dysbiosis.³⁹ 83 This unbalance in the homeostatic microbiome is related to the origin of various types 84 of tumors due, in part, to the modulation of tumor immunity.⁴⁰ with CRC being 85 prominent among these tumor types.⁴¹ Patients with CRC are often characterized by 86 a decrease in beneficial microbiota and an increase in pathogenic opportunistic 87 microorganisms.²² This pathogenic imbalance can have a variety of origins. A 88 89 frequent and often underestimated cause of dysbiosis stems from intensive antibiotic use.42 90

Chronic intestinal inflammation and epithelial disruption, two of the most important 91 risk factors for CRC development, are related to intestinal dysbiosis.^{21, 43} Many of the 92 pathogenic species identified in different studies associated with the development of 93 CRC belong to the group of hydrogen sulfide (H₂S)-producing bacteria. These 94 bacteria can oxidize SCFA, decreasing its levels locally.⁴⁴ H₂S is highly toxic to 95 colonocytes, causes damage to the intestinal epithelium, promotes inflammation, 96 produces metabolic changes, especially through oxidation of butyrate, and can result 97 in the development of CRC.^{45, 46} H₂S is also rapidly absorbed by the mucosa,⁴⁷ which 98 can disrupt the balance between proliferation and apoptosis^{48, 49} and lead to DNA 99

damage.⁵⁰ Furthermore, feces of people at high risk of CRC recurrence have higher concentrations of H_2S .⁵¹ Other studies corroborate these results by finding an increase in *Fusobacterium spp.*, and more specifically *Fusobacterium nucleatum*, an H_2S -producing species, in colonic tumor tissue.^{52, 53} *F. nucleatum* also promotes tumor growth, cell proliferation and the acquisition of chemoresistance in CRC, favoring inflammation and autophagy as a cytoprotective mechanism of the tumor.^{54, 55}

At the phylum level, CRC patients show increased abundance of Proteobacteria 107 and Verrucomicrobia.⁵⁶ Species associated with CRC development include 108 Bacteroides fragilis, Escherichia coli, Peptostreptococcus spp, Enterococcus faecalis, 109 Streptococcus bovis, or Porphyromonas spp.^{22, 53, 57-59} For example, *B. fragilis* and *E.* 110 coli play a key role in the development of familial CRC. In patients with adenomatous 111 112 polyposis, areas arise in the colonic mucosa where *B. fragilis* and *E. coli* accumulate, leading to a local increase in oncotoxins such as *B. fragilis* toxin and colibactin. ⁶⁰ 113 114 These oncotoxins, when transferred to the colon of mice, increase colonic tumor growth and mortality.⁶⁰ In addition, *B. fragilis* levels are elevated in patients with 115 diarrhea, with chronic diarrhea being an important risk factor for the development of 116 CRC.⁶¹ 117

118 Nonetheless, it may not be so simple to discern which bacteria are beneficial. In 119 general, it appears that it may be context-dependent and that one of the key 120 characteristics of a healthy microbiota is its beneficial/harmful microbiota ratio and/or 121 its diversity.

122

1.3. Food and gut microbiota

123 Due to the importance of the microbiota in health and in the origin of diseases such as CRC, there is much interest in knowing how to modify the flora in order to have a 124 125 better homeostatic capacity. The main way in which we can interact directly with our microbiota is through the food we eat.⁶² A study of monozygotic and dizygotic twins, 126 and their mothers, shows that while there is a common core microbiota, pathological 127 128 conditions, such as malnutrition leading to obesity, produce a significant change in the microbiota. These changes result in reduced diversity and modifications in gene 129 expression and metabolic pathways.⁶² Along these lines, it has been shown that a 130 131 "Western" diet (high fat and sugar) can alter the microbiota in periods as short as 1-3 132 days, and that these changes can be reversed by following a healthier diet (high

plant).^{63, 64} These results show that a healthy diet, mainly a plant-based, can improve 133 our microbiota faster than probably any other therapeutic intervention. In fact, 134 135 adherence to a Mediterranean diet has been shown to have a beneficial outcome in 136 modulating the microbiota. Participants following this type of diet had higher levels of 137 SCFA, *Prevotella* and *Firmicutes* that degrade plant fibers, in addition to a higher proportion of bifidobacteria/E. coli and better gastrointestinal habits.⁶⁵ Therefore, it is 138 likely that part of the health benefits of this dietary pattern are due to its effect on our 139 140 commensal flora.

141 In fact, the health benefits of certain dietary patterns, such as fiber consumption, 142 have been evaluated for decades. However, the mechanisms by which fiber 143 decreases the incidence of CRC are not fully understood. Two mechanisms that may 144 be complementary are generally postulated: i) fiber may facilitate gastrointestinal 145 transit decreasing the contact between procancerous substances and ii) the intestinal epithelium, or gut bacteria may ferment fiber, producing SCFA.⁶⁶ In an attempt to 146 147 dissect these mechanisms, a study was conducted using a mouse model in which a representative human microbiota (gnobiotic) was "seeded". It was found that a low-148 149 fiber diet leads to an overgrowth of bacterial species that cause degradation of the 150 mucus lining the intestinal barrier. This makes the barrier more permeable to pathogenic organisms, facilitating the development of colitis.⁶⁷ In this mouse model, 151 with a low-fiber diet, overgrowth of B. caccae and A. muciniphila was promoted, with 152 these two species being responsible for the degradation of intestinal mucus. 153

154 The importance of nutrition is often underestimated in most scientific and medical 155 fields; however, available data show that it is a key tool in modifying the microbiota.

156 **1.4. Probiotics**

Probiotics are defined as "live microorganisms that confer a health benefit when administered in adequate amounts".⁶⁸ The benefits are varied and range from the maintenance of intestinal homeostasis to the prevention of diarrhea, irritable bowel syndrome, and constipation.⁶⁹ In addition, numerous *in vitro*,⁷⁰ preclinical⁷¹⁻⁷³ and clinical studies⁷⁴ have shown that probiotics may have beneficial effects, specifically in cases of CRC.

Probiotics exert their beneficial action by modifying the gut microbiota, improving the gut barrier and its microenvironment, secreting anti-cancer metabolites, and reducing inflammation.⁷⁵ In addition, probiotics have an intimate relationship with the

immune system, particularly through homeostasis of epithelial cell junctions and 166 modulation of T-lymphocytes and dendritic cells activation.^{36, 76} As an example, 167 Butyricicoccus pullicaecorum reduces necrotic enteritis and pathogen abundance in 168 the caecum and ileum in broiler chickens.⁷⁷ Furthermore, its administration promotes 169 the proper functioning of the intestinal epithelial barrier and reduces colitis in 170 preclinical models.³⁰ One of the most widely used probiotics is *A. muciniphila*, which 171 has been shown in numerous studies to have a beneficial role in health maintenance 172 and a therapeutic effect on various diseases such as obesity,⁷⁸ or epithelial tumors.⁷⁹, 173 ⁸⁰ In this regard, it has been used in preclinical models of chronic colitis, where it 174 improved inflammatory parameters and damage in the colon.⁸¹ Additionally, lactic 175 acid bacteria have been frequently used for their health benefits and their 176 immunomodulatory effect,⁸² contributing to inhibiting the development of pathogens.⁸⁹ 177 178 Treatment with L. salivary and L. fermemtum in combination with L. acidophilus can reduce CRC cell proliferation in experimental models.^{83, 84} Furthermore, oral 179 180 administration of 21 different strains of Lachnospiraceae attenuated colorectal inflammation and improved the composition of the microbiota in preclinical models.⁸⁵ 181 However, a meta-analysis evaluating the role of probiotics in cancer patients failed 182 to find a clear overall beneficial outcome, except in reducing the degree of diarrhea, 183

bowel movement, and the need for antidiarrheal drugs.⁸⁶

185 **1.5. Prebiotics**

Prebiotics are defined as "any substance that is selectively utilized by the recipient 186 organism and confers a health benefit".⁸⁷ One of the most studied prebiotics is inulin. 187 188 Inulin is part of a group of dietary fibers known as inulin-type fructans. These compounds are found in numerous foods such as garlic, artichoke, onion and 189 asparagus.⁸⁸ Inulin-type fructans resist digestion in the small intestine and are 190 fermented in the colon, where they are transformed into lactic acid and SCFA, 191 improving intestinal health.^{89, 90} Inulin has been shown to increase levels of CRC-192 protective bacteria such as Bifidobacteria,⁹¹ Bacteroides,⁹² and Akkermansia 193 *muciniphila*⁷⁸ in murine models. 194

The role of resistant starch as a prebiotic has also been examined in numerous pathologies and its benefits have also been suggested in the field of cancer, particularly in CRC.⁹³ Resistant starch is a group of carbohydrates that resist digestion by pancreatic amylase in the small intestine. This type of starch then

reaches the colon where it is fermented by the microbiota, producing numerous protective effects against tumor development, including production of SCFA (butyrate), regulation of bowel movements and the reduction of colonic pH.^{93, 94} Many foods contain resistant starch, such as cereals, vegetables, legumes, seeds, and some nuts.^{93, 95}

Recent studies are using prebiotics as a basis for the synthesis of therapeutic targets for cancer treatment because of their promising role in this field. ⁹⁶

206 **1.6. Symbiotics**

Symbiotics are defined as "a mixture including live microorganisms and substrates, 207 which used selectively by the host organism confers a health benefit".⁹⁷ A distinction 208 is made between cooperative symbiotics, in which probiotic and prebiotic are 209 administered together and act independently contributing to the health benefit, and 210 211 synergistic symbiotics, where the probiotic uses the co-administered prebiotic as a 212 substrate.⁹⁷ The use of symbiotics is becoming increasingly common in the biomedical literature as a method of enhancing the effects of pro- and prebiotics used 213 individually. For example, the combination of *Bifidobacterium animalis subsp. lactis* 214 215 with a resistant starch led to a decrease in the number and incidence of colon 216 neoplasms. Interestingly, the probiotic alone did not produce a similar effect. It was 217 the combination that resulted in protection against cancer development, in part through increased production of SCFA.⁹⁸ 218

Therefore, it seems very promising that symbiotics may play a more effective role than pre- or probiotics alone.

1.7. Oncological treatments and microbiota in CRC

Technological advances and new therapies have dramatically increased the life expectancy of CRC patients.⁶ However, CRC patients often show particularly low responses to hospital treatments.⁹⁹ For this reason, numerous lines of research are being devoted to better understanding the mechanisms underlying this lack of response to treatments, such as immunotherapy.

The first evidence showing the key role that the microbiota plays in modulating the body's immune response to cancer treatment came from a pioneering study showing that microbial flora, and in particular lipopolysaccharide (LPS) from Gram-negative bacteria, increased the activation of dendritic cells and TCD8+ lymphocytes. In this

way, the microbiota promoted melanoma regression after radiotherapy treatment. In 231 contrast, the use of antibiotics, inhibition of LPS and its signaling, significantly 232 diminished the effect of radiotherapy treatment.¹⁰⁰ Numerous studies have 233 corroborated these data, showing that therapies decrease their efficacy in axenic 234 (without microbial flora) or antibiotic-treated mice.^{80, 101-103} A key study in this field 235 showed that genetically identical mice from two different suppliers responded 236 237 unequally to the same cancer treatment, due to differences in microbiota. Not only 238 that, but cohousing or fecal transfer eliminated these differences, clearly pointing towards a key role of microbiota in modulating the efficacy of cancer treatment.¹⁰⁴ 239

Although the role of the microbiota has been studied in different cancer treatments such as radiotherapy,¹⁰⁰ chemotherapy,¹⁰² and surgery,¹⁰⁵ most studies have focused in immunotherapy.^{80, 103} This may be due to both the microbiota's promising role in cancer treatment and its key role in modulating the immune response.

244 **Immunotherapy**

Unfortunately, a large proportion of CRC patients do not respond well to immunotherapy. It is known that the effectiveness of some treatments depends, to a large extent, on the individual's genetics and/or cancer phenotype⁹⁹; however, for a majority of CRC patients, the cause of their lack of response is unknown.

Immunotherapy has promising results in numerous tumor types by inducing 249 immunity by T lymphocytes.¹⁰⁶ Thus, the anti-PD-1 drugs pembrolizumab and 250 251 nivolumab are effective in metastatic patients whose tumors are deficient in DNA mismatch repair (dMMR) enzymes and have high microsatellite instability (MSI-H). 252 253 ⁹⁹For the treatment of refractory dMMR-MSI-H tumors, pembrolizumab and 254 nivolumab combined with an anti-CTLA4, ipilimumab, are used. However, in tumors 255 with active DNA repair enzymes and low microsatellite instability, which account for 85% all tumors, these therapies tend to be ineffective.⁹⁹ Therefore, there is great 256 257 interest in finding methods to improve the efficacy of these therapies in CRC.

Knowing the ideal composition of microbiota to improve the efficacy of immunotherapy treatments is no easy task. It is likely, as mentioned above, that the key lies in increasing the ratio of bacteria that are beneficial to health and decreasing those that are harmful.¹⁰⁷ In this line, mice transplanted with microbiota from CRC patients show, after treatment with anti-PD-1, a decrease in the anti-tumor response in CRC and lower survival, compared to those transplanted with microbiota from

healthy controls.¹¹⁷ Among the bacteria that may be beneficial to improve
immunotherapy are: *Clostridiales, Ruminococcacae, Enterococci, Collinsella, Alistipes, Faecalibacterium spp, A. muciniphila, B. fragilis, Eubacterium linosum* or *Bifidobacteria,* although most studies have been performed on epithelial type
tumors.^{19, 79, 80}

Therefore, the study of the microbiota in the treatment of cancer patients, especially in CRC patients whose treatments do not reach the effectiveness of other types of cancer, is essential.

272 Effect of surgery on the microbiota

273 Colorectal surgery in humans aims for total tumor removal plus the addition of a 274 safety perimeter. When this clean-border surgery is achieved, the likelihood of tumor recurrence decreases considerably.¹⁰⁸ However, local recurrences are common, up 275 276 to 15%, the origin of which appear to be linked to the biology of the primary tumor and/or seeding of the tumor bed during surgery.¹⁰⁹⁻¹¹¹ Most tumors recur at the site of 277 the anastomosis due to incomplete wound closure, the inherent porosity of the 278 junctional area, improper healing, and/or the presence of collagenolytic organisms 279 that increase porosity.^{112, 113} In this regard, a high-fat diet increases the production of 280 colorectal tumors in preclinical models of anastomosis.¹⁰⁵ This mechanism is linked 281 to the overproduction of collagenolytic organisms at the suture site. Pre-operative 282 fecal analysis shows that obese patients respond by increasing collagenolytic micro-283 organisms after taking antibiotics. In contrast, non-obese patients have decreased 284 levels of collagenolytic micro-organisms.¹⁰⁵ 285

Therefore, a healthy microbiota low in collagenolytic microorganisms is key to increasing the chances of successful CRC surgery and avoiding recurrences.

288 **1.8. Study aims**

The overall aim of this work is to review published studies on the modification of the microbiota in CRC.

The specific objectives of this work are to evaluate the impact of modulating the microbiota in CRC patients through; 1) probiotics, 2) prebiotics, 3) symbiotics and 4) nutritional changes. We aim to analyze the potential use of these approaches to modulate the microbiota in CRC patients.

295

296 **2. Methods**

297 2.1. Systematic search

The search strategy was defined between January 15th and April 15th, 2021. The search and filtering in the Pubmed database took place on April 24th, 2021. The language used for the search and filtering of the publications was English. The detailed analysis of the selected publications was carried out from April 25th to May 31st, 2021.

The search strategy included six types of terms: (1) target disease of the study; (2) type of cancer; (3) microbiota and dysbiosis; (4) oncology treatment, (5) use of nutrition and/or supplementation with pro-, pre- and symbiotics and (6) original articles.

To broaden the search terms, asterisks were added to the end of the words. Keywords were combined using the Boolean operators "AND", "OR" and "NOT". The search strategy is detailed in Table 1.

The results of the different levels of the search can be found in the attached supplementary files.

312 Inclusion criteria

Only original articles were selected. Biographies, commentaries, duplicate publications, editorials, guides, interviews, news items, personal narratives, errata, retractions, reviews, systematic reviews and meta-analyses were excluded. In the next level of screening, only articles published in English that had mechanistic results and outcomes, at least *in vivo, were* selected by analysis of the abstract.

³¹⁸ Publications that met the criteria above were downloaded and reviewed.

319 **3. Results**

320 **3.1. Literature search**

Figure 1 shows the flow diagram of the search and selection process. This diagram has been made by adapting the work to the guidelines for systematic searches recommended by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).¹¹⁴ The Pubmed search yielded 202 results. The articles were screened for eligibility criteria. As a result of the first screening, a total of 108 articles

were selected. After applying the next filtering on the type of results, a total of 62 articles remained for analysis. Of these 62 studies, 15 included human clinical trials (**Fig. 1**).

329 **3.2. Characteristics of included results**

Table 2 shows the characteristics of the included studies. The type of intervention 330 331 performed, type of cancer, type of study, impact on the microbiota, the mechanism 332 proposed by the authors, and its impact on cancer development are shown. Finally, 333 the last column includes a more subjective criterion, namely the quality of the data 334 analyzed on a scale ranging from very low = 1, low = 2, medium = 3, high = 4, very high = 5. This criterion has been assessed according to the experimental design, 335 336 statistical analysis and strength of the mechanisms demonstrated. Figure 2 shows 337 the distribution of the included studies.

338 **4. Discussion**

A patient's microbiota plays a key role in modulating the immune system as a natural defense against tumor development and during cancer treatment, especially in CRC.²⁰ However, there is no defined therapeutic strategy for the microbiota in a CRC patient. To make the transition from clinical trials to patient treatment, it is necessary to review all published data on microbiota-related therapeutic approaches in CRC in a systematic way. The therapeutic modulators of the microbiome include primarily probiotics, prebiotics, symbiotics and nutrition.

346 **Probiotics**

One of the most frequent probiotic combinations for the study of CRC is that of 347 Lactobacillus and *Bifidobacterium*. In several studies, pre-inoculation with 348 349 Lactobacillus acidophilus or a cocktail approved for commercial use in China, called Bifico, which consists of Bifidobacterium longum, Lactobacillus acidophilus, and 350 Enterococcus faecalis, reduced colon tumor growth in preclinical models.^{118, 169} Bifico 351 treatment also caused a decrease in Desulfovibrio, Mucispirillum and Odoribacter, 352 associated with an enrichment in *Lactobacillus*.¹¹⁸ However, another study reported 353 354 that a combination of Bifidobacterium and Lactobacillus was not able to improve 5-FU treatment, despite improving the flora composition.¹²³ 355

The mixture of three different strains of Lactobacillus and one of Bifidobacterium 356 decreases the incidence and number of tumors in a preclinical model of CRC 357 associated with colitis.¹³⁰ VSL#3 is a commercial probiotic containing a mixture of 358 different strains of Lactobacillus, Bifidobacterium and Streptococcus. In a murine 359 360 model with a Western diet, treatment with VSL#3 and metformin decreases colonic tumor formation, through reduced cell proliferation and macrophage infiltration, ¹²⁸ 361 However, VSL#3 alone shows no protection against colonic tumor development in 362 other studies.^{116, 128} In fact, in a model of colitis associated with CRC and 363 inflammation, VSL#3 increases macroscopic lesions, as well as their invasiveness 364 and histological grade.¹¹⁶ Therefore, it is important not to prescribe probiotics without 365 scientific basis. 366

367 In addition, the Lactobacillus genus alone is probably the most widely tested 368 probiotic in CRC (Fig. 2 d&e). A study conducted with Lactobacillus casei in a model of CRC associated with colitis, combined with FOLFOX, showed improvement in 369 370 various inflammatory and microbiota parameters; however, it did not show reduction in tumor development.¹²⁴ In this study, FOLFOX increases apoptosis in intestinal 371 epithelial cells, while the probiotic inhibits cell death in healthy epithelial cells.¹²⁴ 372 373 Nonetheless, it is difficult to assess the effect of a given treatment in an animal model, but it is even more complicated in models that use injections of tumor cells in 374 different (heterotopic) locations, as is the case in this study.¹²⁴ Another study with the 375 L. casei BL23 strain showed a total inhibition of the incidence of colorectal tumors in 376 mice. This mechanism could be associated with increased expression of Bik, a 377 proapoptotic gene, and a decrease in Ki67.¹²⁶ Lactobacillus reuteri strain can also 378 379 reduce colon tumors through the production of histamine, which is associated with a decrease in inflammatory markers at both local and systemic levels.¹²⁷ 380

381 Another well-studied probiotic is Akkermansia muciniphila (Fig. 2 d). Several 382 studies support its potential use in CRC patients with promising results. Preclinical studies have shown that it is more efficient against CRC than IL-2 therapy. The 383 384 combination of A. muciniphila and IL-2 was significantly more effective than their separate actions in reducing tumor volume and increasing survival.¹¹⁵ The effect of A. 385 muciniphila appears to be related to a membrane protein called Amuc, which is 386 recognized by Toll-like receptor 2 (TLR2). Cellular mechanisms and immune effects 387 mediated by TLR2 lead to increased efficacy of IL-2 immune therapy.¹¹⁵ 388

Therefore, it seems that probiotics, especially lactic acid bacteria, SCFA producers and *A. muciniphila* could be beneficial for patients diagnosed with CRC.

391 **Prebiotics**

Many of the prebiotics used in the CRC literature are oligo- and polysaccharides 392 (Fig. 2 e & f). Among them, pectin has shown beneficial effects such as SCFA 393 production,¹⁷⁰ reduction of ammonia,¹⁷¹ and improve glucose tolerance.¹⁷² Pectin is 394 the fundamental metabolite of plant walls, and its fermentation serves as a source of 395 396 energy for numerous microorganisms, producing metabolites with beneficial functions for our organism.^{131, 173} Furthermore, pectin is currently used in numerous food 397 additives, so its study is of great interest.^{131, 174} In fact, it has been observed that 398 pectin can be beneficial against several types of tumors such as CRC, breast and 399 prostate cancer by halting tumor development.¹⁷⁴ Its effect seems to be mediated 400 401 through the increase of different SCFA-producing bacteria and in particular acetate, 402 and the enhancement of the immune response through IFN-y-producing TCD8+. In addition, a transplantation of fecal microbiota from PD-1 refractory patients showed 403 enhanced anti-tumor response in PD-1 and pectin-treated mice.¹³¹ 404

Galacto-oligosaccharides derived from lactulose, and mainly lactose, have been 405 tested in preclinical models with promising results in terms of reducing tumor 406 development and modulating the microbiota.¹⁴⁰ Other well-studied oligosaccharides 407 include fructo-oligosaccharides/inulin and mucin.^{66, 132, 164} Inulin has been shown to 408 significantly reduce the volume of subcutaneously transplanted colon tumors, while 409 mucin did not cause any significant change.¹³² In another study, inulin was reported 410 to strongly inhibit tumor development through modification of the microbiota and 411 butyrate production.⁶⁶ This paper dissects the pathways leading to this effect, finding 412 that butyrate is absorbed, but not oxidized due to the Warburg effect of cancer 413 cells.¹⁷⁵ However, healthy colonocytes do use butyrate as a major source of 414 energy.¹⁷⁶ In tumor cells, butyrate accumulates in the cell interior where it inhibits 415 histone deacetylase activity, thus decreasing proliferation and increasing apoptosis.⁶⁶ 416

Studies with compounds derived from citrus peel, such as polymethoxyflavones, have shown positive effects in preventing the development of CRC. However, mechanisms such as autophagy, which the authors highlight as possible effector pathways for these compounds, are poorly analyzed and higher quality studies are needed to draw valid conclusions.¹⁴² Other prebiotics, such as green tea extract

(EGCG), have been shown to reduce colonic tumors, but these studies are of low
scientific quality (grading = 1 and 2) for the reasons mentioned above. In a rat model
of colitis-associated cancer using EGCG and resistant starch, EGCG was shown to
have no effect. Only resistant starch was able to decrease colonic tumor formation
through a change in the microbial flora, increasing SCFA production, and decreasing
inflammation.¹⁵⁴

428 There is great interest among scientists in Asia, but particularly in China, in demonstrating the effects of different therapeutic approaches to traditional medicine 429 through the microbiota.^{135, 148} For example, the Canmei formula contains herbs called 430 Mume sieb and Marci Hieronymi, whose more than 41 active ingredients include DL-431 arginine, L-tyrosine, L(-)-carnitine, adenine, guanine or ambrosic acid. This 432 formulation was shown to decrease the incidence of colonic tumors by reducing 433 inflammation and improving dysbiosis.¹³⁷ Another study using a Boswellia serrata 434 resin extract has also demonstrated, in preclinical models, its ability to reduce colonic 435 tumor formation.¹⁴⁴ Many of these studies present positive results for the inhibition of 436 CRC development. However, in general, they are of low quality (grading = 1 and 2) 437 due to a lack of mechanistic and statistically robust data and therefore do not allow 438 439 for reliable conclusions to be drawn.

440 Symbiotics

One of the most interesting proposals in the literature is the possibility of using 441 symbiotics as therapeutic options to increase the efficacy of available treatments. It 442 443 has been observed that the use of C. butyricum, surrounded by dextran and bound to capecitabine or diclofenac, can increase the efficacy of these chemotherapeutics by 444 445 >500%. This symbiotic decreases tumor invasiveness and also promotes a healthier and more diverse microbiota coupled with increased production of SCFA.⁹⁶ This work 446 is interesting for clinical studies as both dextran and C. butyricum are approved for 447 use in food applications and showed no notable side effects.⁹⁶ Another symbiotic 448 studied is the combination of Lactobacillus gasseri 505 and Cudrania tricuspidata leaf 449 450 extract in fermented milk. This symbiotic was shown to reduce tumor incidence and malignancy in a model of CRC-associated colitis. 146 451

Therefore, the use of symbiotics for improving gut microbiota in patients with CRC seems promising, although more studies are needed to clearly define which symbiotic should be used, the dose, the timing, and in which specific CRC patients.

455 Healthy nutrition as a source of pre- and probiotics

456 Most, if not all pro-, pre- and symbiotics can be obtained naturally through a healthy 457 diet. Prebiotics have been isolated from mushrooms,¹³⁸ fruits,^{142, 151} dairy,¹⁴⁰ rice,¹⁶¹ 458 and green tea¹³⁸ and probiotics from fruit skins,¹¹⁷ dairy,¹²² and fermented 459 products.¹⁴⁶

From infancy, a balanced, non-processed plant-based nutrition is the best way to have a proper gut microbiota. In fact, it has been shown that a diet high in soluble fiber is not able to reverse the erosion of intestinal mucus caused by a diet without fiber. However, the same diet, but high in intact plant fiber decreased mucus degradation, strengthening the intestinal barrier.⁶⁷

Anthocyanins, compounds with a positive impact on the health of patients with CRC, are present in many foods such as tea, coffee, cocoa and red fruits. ¹⁷⁷ In this regard, it has been shown that anthocyanins in blackberries can reduce the incidence of CRC, through diminished local inflammation and improved microbiota.¹⁵¹

Another food with interesting results is the marine extract of certain shellfish that 469 470 may have anticarcinogenic effects. Using metabolomic analysis techniques, one can discern which compounds are toxic to tumor cells, opening the door to precision 471 nutrition.^{147, 178} Algae-derived products such as fucoxanthin, a carotenoid present in 472 473 high levels in wakame (Undaria pinnatifida), have also shown to decrease the 474 number of adenocarcinomas and total tumors. This effect was also associated with an increase in the number of Lachnospiraceae.¹³⁴ Spices have similarly attracted a 475 great deal of interest for their health-promoting properties. For example, nutmeg can 476 decrease the development of APC genetically engineered tumors by modulating the 477 metabolism of the microbial flora and improving lipid metabolism.¹⁵⁰ Numerous food 478 extracts are also used in traditional Chinese medicine, including American ginseng. 479 480 The use of this compound in a murine model prevented tumors and ameliorated dysbiosis induced by different murine models of CRC and high-fat diet.^{153, 155} 481

Moving from specific foods to dietary patterns, the Mediterranean diet has been shown to have beneficial effects on multiple levels, specifically in the prevention of certain types of cancer.¹⁷⁹ In the case of CRC, epidemiological studies show that adherence to a Mediterranean diet reduces the incidence of CRC by up to 11%.¹⁸⁰ Likewise, the effect of mixing a Mediterranean diet with other types of diet (low-fat or high-fat Western-type diet) has been studied in models of cancer associated with

colitis. This study showed that consumption of the Mediterranean diet, regardless of
 the diet with which it was mixed, decreased tumor incidence, and improved the
 microbiota, especially when accompanying a high-fat diet. ¹⁴⁹

491 Randomized clinical trials

At the highest level of scientific evidence are randomized clinical trials. Within this 492 493 group, those conducted with lactic acid strains stand out. Among them, a study 494 conducted with 78 patients analyzed the role of probiotics in reducing side effects 495 after CRC surgery. Inclusion criteria were a diagnosis of stage III adenomatous CRC 496 and that the patients were to undergo surgery. The probiotic group received postoperative treatment with a mixture of different strains of Lactobacillus, 497 Bifidobacterium, and Streptococcus thermophilus for almost one year. The most 498 499 important conclusion of this study was that probiotic treatment decreased the most 500 frequent side effects of surgery, specifically paralytic ileus. However, limitations of this study include the low number of subjects included, the apparent lack of double-501 blinding, active placebo, and a weak statistical analysis.⁷⁴ In another clinical trial, a 502 probiotic consisting of Bifidobacterium longum, Lactobacillus acidophilus and 503 504 Enterococcus faecalis was tested in CRC patients undergoing surgery. It was shown 505 that, in addition to improving the diversity of the microbial flora, the probiotic mixture 506 was able to decrease the levels of Fusobacterium, a bacterium associated with the development of CRC, by >500%.¹⁵⁶ In addition, its use decreased post-operative 507 infections.¹⁵⁷ Another similar probiotic mixture consisting of Lactobacillus plantarum, 508 509 Lactobacillus acidophilus and Bifidobacterium longum reduced the risk of postoperative infection and improved the intestinal epithelial barrier, resulting in a 510 lower incidence of diarrhea, abdominal pain, and fever.¹⁵⁹ A study using a mixture of 511 Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) showed that only 512 the latter (La1) colonized the gut, reducing the number of pathogenic microorganisms 513 and reducing colonic inflammation in CRC patients undergoing surgery. This result 514 515 shows that adding more probiotics will not have a greater effect and it is important to 516 study each strain individually and its combination before it can be recommended to patients.¹⁶⁰ 517

In another clinical trial, a probiotic mixture consisting of *Enterococcus, Clostridium* and *Bacillus* was used in patients undergoing CRC surgery to discern whether their consumption could ameliorate the adverse effects of surgery. It was found that peri-

surgical use of this mixture significantly reduced incisional infections and decreased 521 the acute inflammatory response to surgery.¹⁵⁸ However, in this study, no 522 randomization was performed, and patients were included in one group (control) or 523 524 the other (probiotic) according to the date of surgery, with the control group (2009-525 2011) prior to the probiotic group (2011-2013). This does not allow for a clear 526 conclusion on the effect of the probiotic, because multiple factors may have changed 527 during those two years, including greater experience of the surgical team or better 528 technical means. In this regard, the authors describe that a higher number of 529 laparotomies were performed in the probiotic group, and that performing or not performing laparotomy is a key factor related to the outcome of the surgery.¹⁵⁸ 530

As far as prebiotics are concerned, rice bran is of great interest due to its large commercial use. Numerous studies show the benefit of whole grain consumption in the prevention of CRC.¹⁸¹ In the case of rice bran, various phytochemicals in its composition have been associated with a decrease in the risk of cancer development, in particular CRC.¹⁸² Its consumption increases levels of *Firmicutes* and *Lactobacillus*¹⁶¹ and produces numerous metabolic modifications that could be related to a decrease in the risk of developing CRC.¹⁶⁶

538 In another clinical trial with prebiotics in CRC patients, a mixture of different non-539 digestible oligosaccharides was used for 7 days before patients underwent radical 540 surgery to remove the tumor. Both groups received the same nutrition (provided by the hospital) in the 7 days before and after surgery (parenteral nutrition). Surgery 541 542 decreased the diversity of the microbiota in both groups, underlining the impact of 543 these interventions on gut health. Interestingly, a principal component analysis of 544 microbiome diversity was able to unequivocally identify samples from postoperative patients who had received prebiotics. Furthermore, the use of these prebiotics 545 improved systemic immune function, confirming the positive effect that microbiota 546 can have on immune response. An important limitation of this study is that the 547 randomization did not specify the stage or type of tumor.¹⁶² 548

549 Symbiotics have also been tested in randomized clinical trials. A commercially 550 named symbiotic, simbioflora®, containing fructooligosaccharides, 3 strains of 551 *Lactobacillus,* and *Bifidobacterium lactis* showed promising results in CRC patients 552 undergoing surgery. The use of this symbiotic significantly reduced inflammation and 553 postoperative infections.¹⁶³ However, this is a small study of patients with cancer at 554 different stages, so the data should be analyzed with caution. In another study, a

mixture of Bifidobacterium, Lactobacillus and inulin strains was used in stage I-III 555 556 patients undergoing surgery. This treatment resulted in an improvement in the composition of the microbial community, especially the SCFA-producing bacterium. 557 558 However, this study does not define blind randomization of patients and there is no placebo, so the data should be also analyzed with caution.¹⁶⁴ Finally, a randomized 559 clinical study was conducted in 20 healthy subjects with backcrossed arms with the 560 561 aim of preventing CRC. This study of 4 weeks duration per intervention (switching 562 every 4 weeks to another arm until each group completed all 4) was done with 4 563 different arms: placebo, Bifidobacterium lactis, resistant starch and their combination (Bifidobacterium lactis and resistant starch). It was shown that in healthy subjects the 564 565 combination of Bifidobacterium lactis and resistant starch increased the levels of 566 Lachnospiraceae spp. However, the other parameters analyzed, such as stool mass, 567 pH or ammonium, SCFA, circulating cytokines, and markers of colonic epithelial health, did not change.¹⁶⁵ 568

The use of pomegranate extract in patients undergoing surgical tumor resection has also been investigated. Pomegranate extract was shown to produce significant changes in the expression of numerous genes and microRNAs related to tumor development. These results underline the crucial role of diet in modifying gene expression and, therefore, in the etiology of disease.^{167, 168}

574 **5. Conclusion**

575 We can summarize the conclusions of this work regarding the modification of the 576 microbiota in the CRC patient as follows:

577 1) Antibiotic use is one of the major deleterious factors for the prognosis of
 578 treatment efficacy, due to its harmful effect on the microbiota.

- 2) **Prebiotics** such as inulin and resistant starch can support the development of a
 healthy microbiota.
- 3) **Probiotics**, mainly based on **SCFA-producing lactic acid strains**, show a favorable profile in preclinical and clinical studies. However, not all strains are equally favorable and are therefore <u>not recommended for use in patients without</u> <u>individualized study of the patient and the probiotic</u>.
- 4) A healthy and varied nutrition, consisting mainly of unprocessed plant-based
 foods, seems to be one of the best sources to maintain a homeostatic microbiota.

Finally, after a detailed analysis of the literature, in a **healthy person**, there is no <u>need</u> to recommend the use of <u>pre-</u>, <u>pro-</u> or <u>symbiotics</u> in addition to a **healthy diet**. However, CRC patients often have <u>severe dysbiosis</u> due to their own disease, and broad-spectrum antibiotic use. In these patients, apart from a **healthy diet**, or if a healthy diet cannot be established, <u>carefully chosen pre-</u>, <u>pro-</u> and/or <u>symbiotics</u> may <u>be beneficial to</u> restore a beneficial microbiota and support the efficacy of hospital treatments more effectively.

594

595 Acknowledgements

596 We thank Dr. Alberto Canfran-Duque and Noemi Rotllan for their for critical reading 597 of the manuscript. We apologize to those whose work could not be cited owing to 598 space limitations.

599

600 Authors Contributions

JMM designed and performed the systematic search, wrote and edited the manuscript. SBE contributed to the editing and interpretation of the manuscript. All authors read and edited the final draft of the manuscript.

604

605 Competing Financial Interest

606 The authors declare no conflicts of interest

607

608 Correspondence and requests for materials should be addressed to: madrigal-609 matute@ibions.com.

610

611 Data availability

612 There are not restrictions on data availability in this manuscript.

613

614

616

617 **6. Bibliography**

Henrikson, N.B. *et al.* Family history and the natural history of colorectal
 cancer: systematic review. *Genet Med* **17**, 702-712 (2015).

2. Czene, K., Lichtenstein, P. & Hemminki, K. Environmental and heritable
causes of cancer among 9.6 million individuals in the Swedish Family-Cancer
Database. *Int J Cancer* 99, 260-266 (2002).

3. Lichtenstein, P. *et al.* Environmental and heritable factors in the causation of
cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 343, 78-85 (2000).

4. Jiao, S. *et al.* Estimating the heritability of colorectal cancer. *Hum Mol Genet*23, 3898-3905 (2014).

5. Syngal, S. *et al.* ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol* **110**, 223-262; quiz 263 (2015).

631 6. Dekker, E., Tanis, P.J., Vleugels, J.L.A., Kasi, P.M. & Wallace, M.B. Colorectal 632 cancer. *Lancet* **394**, 1467-1480 (2019).

7. Nishida, A. *et al.* Gut microbiota in the pathogenesis of inflammatory bowel
disease. *Clin J Gastroenterol* **11**, 1-10 (2018).

8. Murphy, N. *et al.* Lifestyle and dietary environmental factors in colorectal
cancer susceptibility. *Mol Aspects Med* 69, 2-9 (2019).

637 9. Crosnier, C., Stamataki, D. & Lewis, J. Organizing cell renewal in the intestine:
638 stem cells, signals and combinatorial control. *Nat Rev Genet* 7, 349-359 (2006).

10. (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.

Lyon (FR): International Agency for Research on Cancer; 2010. (IARC Monographs
on the Evaluation of Carcinogenic Risks to Humans, No. 92.); 2010).

Mottram, D.S., Wedzicha, B.L. & Dodson, A.T. Acrylamide is formed in the
Maillard reaction. *Nature* **419**, 448-449 (2002).

12. (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
Chemical Agents and Related Occupations. Lyon (FR): International Agency for
Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic
Risks to Humans, No. 100F.) 2012).

Diggs, D.L. et al. Polycyclic aromatic hydrocarbons and digestive tract 648 13. 649 cancers: a perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 29, 650 324-357 (2011). 14. Tabatabaei, S.M., Heyworth, J.S., Knuiman, M.W. & Fritschi, L. Dietary 651 benzo[a]pyrene intake from meat and the risk of colorectal cancer. Cancer Epidemiol 652 Biomarkers Prev 19, 3182-3184 (2010). 653 15. Coussens, L.M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 654 655 (2002).656 16. Medema, J.P. Cancer stem cells: the challenges ahead. Nat Cell Biol 15, 338-657 344 (2013). 658 17. Cancer Genome Atlas, N. Comprehensive molecular characterization of 659 human colon and rectal cancer. Nature 487, 330-337 (2012). 660 18. Stappenbeck, T.S. & Virgin, H.W. Accounting for reciprocal host-microbiome interactions in experimental science. Nature 534, 191-199 (2016). 661 662 19. Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. & Gajewski, T.F. The microbiome 663 in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science 359, 664 1366-1370 (2018). 665 20. Thursby, E. & Juge, N. Introduction to the human gut microbiota. Biochem J 666 474, 1823-1836 (2017). 21. Claesson, M.J. et al. Gut microbiota composition correlates with diet and 667 health in the elderly. Nature 488, 178-184 (2012). 668 22. Wang, T. et al. Structural segregation of gut microbiota between colorectal 669 cancer patients and healthy volunteers. ISME J 6, 320-329 (2012). 670 671 23. Lin, Y. et al. NMR-based fecal metabolomics fingerprinting as predictors of 672 earlier diagnosis in patients with colorectal cancer. Oncotarget 7, 29454-29464 (2016). 673 24. Chen, J. & Vitetta, L. Inflammation-Modulating Effect of Butyrate in the 674 Prevention of Colon Cancer by Dietary Fiber. Clin Colorectal Cancer 17, e541-e544 675 676 (2018). 25. Zeng, H., Safratowich, B.D., Wang, T.T.Y., Hamlin, S.K. & Johnson, L.K. 677 678 Butyrate Inhibits Deoxycholic-Acid-Resistant Colonic Cell Proliferation via Cell Cycle 679 Arrest and Apoptosis: A Potential Pathway Linking Dietary Fiber to Cancer 680 Prevention. *Mol Nutr Food Res* **64**, e1901014 (2020).

26. Tan, J. *et al.* The role of short-chain fatty acids in health and disease. *Adv Immunol* **121**, 91-119 (2014).

683 27. Ganapathy, V., Thangaraju, M., Prasad, P.D., Martin, P.M. & Singh, N.
684 Transporters and receptors for short-chain fatty acids as the molecular link between
685 colonic bacteria and the host. *Curr Opin Pharmacol* **13**, 869-874 (2013).

28. Zhao, Y. *et al.* GPR43 mediates microbiota metabolite SCFA regulation of
antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR
and STAT3. *Mucosal Immunol* **11**, 752-762 (2018).

Madara, J.L. & Pappenheimer, J.R. Structural basis for physiological
 regulation of paracellular pathways in intestinal epithelia. *J Membr Biol* 100, 149-164
 (1987).

30. Eeckhaut, V. *et al.* Butyricicoccus pullicaecorum in inflammatory bowel
disease. *Gut* 62, 1745-1752 (2013).

- Kang, S. *et al.* Dysbiosis of fecal microbiota in Crohn's disease patients as
 revealed by a custom phylogenetic microarray. *Inflamm Bowel Dis* 16, 2034-2042
 (2010).
- 32. Takaishi, H. *et al.* Imbalance in intestinal microflora constitution could be
 involved in the pathogenesis of inflammatory bowel disease. *Int J Med Microbiol* 298,
 463-472 (2008).

33. Karlsson, C.L. *et al.* The microbiota of the gut in preschool children with
normal and excessive body weight. *Obesity (Silver Spring)* 20, 2257-2261 (2012).

34. Crovesy, L., Masterson, D. & Rosado, E.L. Profile of the gut microbiota of
adults with obesity: a systematic review. *Eur J Clin Nutr* **74**, 1251-1262 (2020).

35. Vigsnaes, L.K., Brynskov, J., Steenholdt, C., Wilcks, A. & Licht, T.R. Gramnegative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls. *Benef Microbes* **3**, 287-297 (2012).

36. Wang, L. *et al.* A purified membrane protein from Akkermansia muciniphila or
the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of
CD8(+) T cells in mice. *Gut* 69, 1988-1997 (2020).

37. Ottman, N. *et al.* Genome-Scale Model and Omics Analysis of Metabolic
Capacities of Akkermansia muciniphila Reveal a Preferential Mucin-Degrading
Lifestyle. *Appl Environ Microbiol* 83 (2017).

38. Wang, G. *et al.* Role of SCFAs in gut microbiome and glycolysis for colorectal
cancer therapy. *J Cell Physiol* **234**, 17023-17049 (2019).

- 39. Petersen, C. & Round, J.L. Defining dysbiosis and its influence on host
 immunity and disease. *Cell Microbiol* 16, 1024-1033 (2014).
- 40. Wong, S.H. & Yu, J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. *Nat Rev Gastroenterol Hepatol* **16**, 690-704 (2019).
- 41. Peters, B.A. *et al.* The gut microbiota in conventional and serrated precursors of colorectal cancer. *Microbiome* **4**, 69 (2016).
- 42. Dethlefsen, L., Huse, S., Sogin, M.L. & Relman, D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol* **6**, e280 (2008).
- 43. Henao-Mejia, J. *et al.* Inflammasome-mediated dysbiosis regulates
 progression of NAFLD and obesity. *Nature* 482, 179-185 (2012).
- 44. Newton, D.F., Cummings, J.H., Macfarlane, S. & Macfarlane, G.T. Growth of a
 human intestinal Desulfovibrio desulfuricans in continuous cultures containing
 defined populations of saccharolytic and amino acid fermenting bacteria. *J Appl Microbiol* 85, 372-380 (1998).
- 45. Carbonero, F., Benefiel, A.C. & Gaskins, H.R. Contributions of the microbial
 hydrogen economy to colonic homeostasis. *Nat Rev Gastroenterol Hepatol* 9, 504518 (2012).
- 46. Roediger, W.E., Duncan, A., Kapaniris, O. & Millard, S. Reducing sulfur
 compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. *Gastroenterology* **104**, 802-809 (1993).
- 47. Suarez, F., Furne, J., Springfield, J. & Levitt, M. Production and elimination of
 sulfur-containing gases in the rat colon. *Am J Physiol* **274**, G727-733 (1998).
- 48. Cai, W.J., Wang, M.J., Ju, L.H., Wang, C. & Zhu, Y.C. Hydrogen sulfide
 induces human colon cancer cell proliferation: role of Akt, ERK and p21. *Cell Biol Int*34, 565-572 (2010).
- 49. Deplancke, B. & Gaskins, H.R. Hydrogen sulfide induces serum-independent
 cell cycle entry in nontransformed rat intestinal epithelial cells. *FASEB J* 17, 13101312 (2003).
- 50. Attene-Ramos, M.S., Wagner, E.D., Plewa, M.J. & Gaskins, H.R. Evidence
 that hydrogen sulfide is a genotoxic agent. *Mol Cancer Res* 4, 9-14 (2006).
 - 27

51. Kanazawa, K. *et al.* Factors influencing the development of sigmoid colon cancer. Bacteriologic and biochemical studies. *Cancer* **77**, 1701-1706 (1996).

52. Kostic, A.D. *et al.* Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. *Genome Res* **22**, 292-298 (2012).

53. Castellarin, M. *et al.* Fusobacterium nucleatum infection is prevalent in human
colorectal carcinoma. *Genome Res* 22, 299-306 (2012).

54. Yang, Y. et al. Fusobacterium nucleatum Increases Proliferation of Colorectal

754 Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4

Signaling to Nuclear Factor-kappaB, and Up-regulating Expression of MicroRNA-21.

756 *Gastroenterology* **152**, 851-866 e824 (2017).

757 55. Yu, T. *et al.* Fusobacterium nucleatum Promotes Chemoresistance to 758 Colorectal Cancer by Modulating Autophagy. *Cell* **170**, 548-563 e516 (2017).

56. Campisciano, G. *et al.* The Obesity-Related Gut Bacterial and Viral Dysbiosis
Can Impact the Risk of Colon Cancer Development. *Microorganisms* 8 (2020).

57. Feng, Q. *et al.* Gut microbiome development along the colorectal adenomacarcinoma sequence. *Nat Commun* 6, 6528 (2015).

763 58. Arthur, J.C. *et al.* Intestinal inflammation targets cancer-inducing activity of the
764 microbiota. *Science* 338, 120-123 (2012).

59. Garrett, W.S. The gut microbiota and colon cancer. *Science* 364, 1133-1135
(2019).

60. Dejea, C.M. *et al.* Patients with familial adenomatous polyposis harbor colonic
biofilms containing tumorigenic bacteria. *Science* **359**, 592-597 (2018).

61. Zhang, G., Svenungsson, B., Karnell, A. & Weintraub, A. Prevalence of enterotoxigenic Bacteroides fragilis in adult patients with diarrhea and healthy controls. *Clin Infect Dis* **29**, 590-594 (1999).

Turnbaugh, P.J. *et al.* A core gut microbiome in obese and lean twins. *Nature* **457**, 480-484 (2009).

63. Turnbaugh, P.J. *et al.* The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Sci Transl Med* **1**, 6ra14 (2009).

64. Carmody, R.N. *et al.* Diet dominates host genotype in shaping the murine gut
microbiota. *Cell Host Microbe* **17**, 72-84 (2015).

779 65. De Filippis, F. *et al.* High-level adherence to a Mediterranean diet beneficially
780 impacts the gut microbiota and associated metabolome. *Gut* 65, 1812-1821 (2016).

66. Donohoe, D.R. *et al.* A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyratedependent manner. *Cancer Discov* **4**, 1387-1397 (2014).

67. Desai, M.S. *et al.* A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. *Cell* **167**, 1339-1353 e1321 (2016).

68. Halmos, E.P., Power, V.A., Shepherd, S.J., Gibson, P.R. & Muir, J.G. A diet
low in FODMAPs reduces symptoms of irritable bowel syndrome. *Gastroenterology* **146**, 67-75 e65 (2014).

69. Sanders, M.E., Merenstein, D.J., Reid, G., Gibson, G.R. & Rastall, R.A.
Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nat Rev Gastroenterol Hepatol* **16**, 605-616 (2019).

793 70. Nami, Y., Haghshenas, B., Haghshenas, M., Abdullah, N. & Yari 794 Khosroushahi, A. The Prophylactic Effect of Probiotic Enterococcus lactis IW5 795 against Different Human Cancer Cells. *Front Microbiol* **6**, 1317 (2015).

796 71. Kaeid Sharaf, L. & Shukla, G. Probiotics (Lactobacillus acidophilus and
 797 Lactobacillus rhamnosus GG) in Conjunction with Celecoxib (selective COX-2
 798 inhibitor) Modulated DMH-Induced Early Experimental Colon Carcinogenesis. *Nutr* 799 *Cancer* 70, 946-955 (2018).

Sharaf, L.K., Sharma, M., Chandel, D. & Shukla, G. Prophylactic intervention
 of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated
 apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. *BMC Cancer* 18, 1111 (2018).

73. Li, J. *et al.* Probiotics modulated gut microbiota suppresses hepatocellular
carcinoma growth in mice. *Proc Natl Acad Sci U S A* **113**, E1306-1315 (2016).

806 74. Bajramagic, S. *et al.* Usage of Probiotics and its Clinical Significance at
807 Surgically Treated Patients Sufferig from Colorectal Carcinoma. *Med Arch* **73**, 316808 320 (2019).

75. Azcarate-Peril, M.A., Sikes, M. & Bruno-Barcena, J.M. The intestinal
microbiota, gastrointestinal environment and colorectal cancer: a putative role for
probiotics in prevention of colorectal cancer? *Am J Physiol Gastrointest Liver Physiol* **301**, G401-424 (2011).

76. Zhuo, Q. *et al.* Lysates of Lactobacillus acidophilus combined with CTLA-4blocking antibodies enhance antitumor immunity in a mouse colon cancer model. *Sci Rep* 9, 20128 (2019).

816 77. Eeckhaut, V. *et al.* The Probiotic Butyricicoccus pullicaecorum Reduces Feed
817 Conversion and Protects from Potentially Harmful Intestinal Microorganisms and
818 Necrotic Enteritis in Broilers. *Front Microbiol* **7**, 1416 (2016).

78. Everard, A. *et al.* Cross-talk between Akkermansia muciniphila and intestinal
epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A* **110**, 9066-9071
(2013).

79. Gopalakrishnan, V. *et al.* Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science* **359**, 97-103 (2018).

824 80. Routy, B. *et al.* Gut microbiome influences efficacy of PD-1-based 825 immunotherapy against epithelial tumors. *Science* **359**, 91-97 (2018).

826 81. Zhai, R. *et al.* Strain-Specific Anti-inflammatory Properties of Two 827 Akkermansia muciniphila Strains on Chronic Colitis in Mice. *Front Cell Infect* 828 *Microbiol* **9**, 239 (2019).

829 82. Paolillo, R., Romano Carratelli, C., Sorrentino, S., Mazzola, N. & Rizzo, A.
830 Immunomodulatory effects of Lactobacillus plantarum on human colon cancer cells.
831 Int Immunopharmacol 9, 1265-1271 (2009).

832 83. Kahouli, I., Malhotra, M., Westfall, S., Alaoui-Jamali, M.A. & Prakash, S.
833 Design and validation of an orally administrated active L. fermentum-L. acidophilus
834 probiotic formulation using colorectal cancer Apc (Min/+) mouse model. *Appl*835 *Microbiol Biotechnol* **101**, 1999-2019 (2017).

836 84. Zhu, J. *et al.* Lactobacillus salivarius Ren prevent the early colorectal 837 carcinogenesis in 1, 2-dimethylhydrazine-induced rat model. *J Appl Microbiol* **117**, 838 208-216 (2014).

839 85. Chen, L. *et al.* NLRP12 attenuates colon inflammation by maintaining colonic
840 microbial diversity and promoting protective commensal bacterial growth. *Nat*841 *Immunol* 18, 541-551 (2017).

842 86. Redman, M.G., Ward, E.J. & Phillips, R.S. The efficacy and safety of 843 probiotics in people with cancer: a systematic review. *Ann Oncol* **25**, 1919-1929 844 (2014).

845 87. Gibson, G.R. *et al.* Expert consensus document: The International Scientific 846 Association for Probiotics and Prebiotics (ISAPP) consensus statement on the

definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol* **14**, 491-502 (2017).

849 88. van Loo, J., Coussement, P., de Leenheer, L., Hoebregs, H. & Smits, G. On

the presence of inulin and oligofructose as natural ingredients in the western diet. Crit

851 *Rev Food Sci Nutr* **35**, 525-552 (1995).

852 89. Roberfroid, M.B., Van Loo, J.A. & Gibson, G.R. The bifidogenic nature of 853 chicory inulin and its hydrolysis products. *J Nutr* **128**, 11-19 (1998).

90. Campbell, J.M., Fahey, G.C., Jr. & Wolf, B.W. Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. *J Nutr* **127**, 130-136 (1997).

91. Fehlbaum, S. *et al.* In Vitro Fermentation of Selected Prebiotics and Their
Effects on the Composition and Activity of the Adult Gut Microbiota. *Int J Mol Sci* 19
(2018).

92. Li, K. *et al.* Dietary inulin alleviates diverse stages of type 2 diabetes mellitus
via anti-inflammation and modulating gut microbiota in db/db mice. *Food Funct* 10,
1915-1927 (2019).

93. Fuentes-Zaragoza, E. *et al.* Resistant starch as prebiotic: A review. *Starch* -*Stärke* 63, 406-415 (2011).

94. Sharma, A., Yadav, B.S. & Ritika Resistant Starch: Physiological Roles and
Food Applications. *Food Reviews International* 24, 193-234 (2008).

95. Faraj, A., Vasanthan, T. & Hoover, R. The effect of extrusion cooking on resistant starch formation in waxy and regular barley flours. *Food Research International* **37**, 517-525 (2004).

870 96. Zheng, D.W. *et al.* Prebiotics-Encapsulated Probiotic Spores Regulate Gut
871 Microbiota and Suppress Colon Cancer. *Adv Mater* 32, e2004529 (2020).

97. Swanson, K.S. *et al.* The International Scientific Association for Probiotics and
Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. *Nat Rev Gastroenterol Hepatol* **17**, 687-701 (2020).

98. Le Leu, R.K., Hu, Y., Brown, I.L., Woodman, R.J. & Young, G.P. Synbiotic intervention of Bifidobacterium lactis and resistant starch protects against colorectal cancer development in rats. *Carcinogenesis* **31**, 246-251 (2010).

878 99. Ganesh, K. *et al.* Immunotherapy in colorectal cancer: rationale, challenges
879 and potential. *Nat Rev Gastroenterol Hepatol* **16**, 361-375 (2019).

100. Paulos, C.M. *et al.* Microbial translocation augments the function of adoptively

transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 117,

882 2197-2204 (2007).

101. lida, N. *et al.* Commensal bacteria control cancer response to therapy by
 modulating the tumor microenvironment. *Science* 342, 967-970 (2013).

102. Viaud, S. *et al.* The intestinal microbiota modulates the anticancer immune
effects of cyclophosphamide. *Science* 342, 971-976 (2013).

- 103. Vetizou, M. *et al.* Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science* **350**, 1079-1084 (2015).
- 104. Sivan, A. *et al.* Commensal Bifidobacterium promotes antitumor immunity and
 facilitates anti-PD-L1 efficacy. *Science* **350**, 1084-1089 (2015).

891 105. Gaines, S. *et al.* Western Diet Promotes Intestinal Colonization by
892 Collagenolytic Microbes and Promotes Tumor Formation After Colorectal Surgery.

893 *Gastroenterology* **158**, 958-970 e952 (2020).

106. Chen, D.S. & Mellman, I. Elements of cancer immunity and the cancer–
immune set point. *Nature* 541, 321-330 (2017).

107. Matson, V. *et al.* The commensal microbiome is associated with anti-PD-1
efficacy in metastatic melanoma patients. *Science* **359**, 104-108 (2018).

108. Alberda, W.J. *et al.* The Importance of a Minimal Tumor-Free Resection
Margin in Locally Recurrent Rectal Cancer. *Dis Colon Rectum* 58, 677-685 (2015).

109. Manfredi, S. *et al.* Incidence and patterns of recurrence after resection for cure
of colonic cancer in a well defined population. *Br J Surg* **93**, 1115-1122 (2006).

110. Naxerova, K. *et al.* Origins of lymphatic and distant metastases in human colorectal cancer. *Science* **357**, 55-60 (2017).

111. Fermor, B., Umpleby, H.C., Lever, J.V., Symes, M.O. & Williamson, R.C.
Proliferative and metastatic potential of exfoliated colorectal cancer cells. *J Natl Cancer Inst* **76**, 347-349 (1986).

907 112. Shogan, B.D. *et al.* Collagen degradation and MMP9 activation by
908 Enterococcus faecalis contribute to intestinal anastomotic leak. *Sci Transl Med* 7,
909 286ra268 (2015).

910 113. Mirnezami, A. *et al.* Increased local recurrence and reduced survival from
911 colorectal cancer following anastomotic leak: systematic review and meta-analysis.
912 *Ann Surg* **253**, 890-899 (2011).

114. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. & Group, P. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 6, e1000097 (2009).

916 115. Shi, L. *et al.* Combining IL-2-based immunotherapy with commensal probiotics
917 produces enhanced antitumor immune response and tumor clearance. *J Immunother*918 *Cancer* 8 (2020).

116. Arthur, J.C. *et al.* VSL#3 probiotic modifies mucosal microbial composition but
does not reduce colitis-associated colorectal cancer. *Sci Rep* **3**, 2868 (2013).

117. Chandel, D., Sharma, M., Chawla, V., Sachdeva, N. & Shukla, G. Isolation,
characterization and identification of antigenotoxic and anticancerous indigenous
probiotics and their prophylactic potential in experimental colon carcinogenesis. *Sci Rep* **9**, 14769 (2019).

118. Song, H. *et al.* Pretreatment with probiotic Bifico ameliorates colitis-associated
cancer in mice: Transcriptome and gut flora profiling. *Cancer Sci* **109**, 666-677
(2018).

119. Xu, H. *et al.* Inhibitory Effects of Breast Milk-Derived Lactobacillus rhamnosus
Probio-M9 on Colitis-Associated Carcinogenesis by Restoration of the Gut Microbiota
in a Mouse Model. *Nutrients* 13 (2021).

120. Chang, S.C. *et al.* A gut butyrate-producing bacterium Butyricicoccus
pullicaecorum regulates short-chain fatty acid transporter and receptor to reduce the
progression of 1,2-dimethylhydrazine-associated colorectal cancer. *Oncol Lett* 20,
327 (2020).

121. Hradicka, P., Beal, J., Kassayova, M., Foey, A. & Demeckova, V. A Novel
Lactic Acid Bacteria Mixture: Macrophage-Targeted Prophylactic Intervention in
Colorectal Cancer Management. *Microorganisms* 8 (2020).

938 122. Silveira, D.S.C. *et al.* Lactobacillus bulgaricus inhibits colitis-associated cancer
939 via a negative regulation of intestinal inflammation in azoxymethane/dextran sodium
940 sulfate model. *World J Gastroenterol* 26, 6782-6794 (2020).

941 123. Yuan, L. *et al.* The influence of gut microbiota dysbiosis to the efficacy of 5942 Fluorouracil treatment on colorectal cancer. *Biomed Pharmacother* **108**, 184-193
943 (2018).

124. Chang, C.W. *et al.* Lactobacillus casei Variety rhamnosus Probiotic
Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a
Syngeneic Colorectal Cancer Model. *Front Microbiol* **9**, 983 (2018).

947 125. Bindels, L.B. *et al.* Increased gut permeability in cancer cachexia: mechanisms
948 and clinical relevance. *Oncotarget* 9, 18224-18238 (2018).

126. Jacouton, E., Chain, F., Sokol, H., Langella, P. & Bermudez-Humaran, L.G.

Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal
Cancer. *Front Immunol* 8, 1553 (2017).

127. Gao, C. *et al.* Gut Microbe-Mediated Suppression of Inflammation-Associated

Colon Carcinogenesis by Luminal Histamine Production. *Am J Pathol* 187, 23232336 (2017).

128. Chung, E.J. *et al.* Combination of metformin and VSL#3 additively suppresses
western-style diet induced colon cancer in mice. *Eur J Pharmacol* **794**, 1-7 (2017).

129. da Silva Duarte, V. *et al.* Chemoprevention of DMH-Induced Early Colon
Carcinogenesis in Male BALB/c Mice by Administration of Lactobacillus Paracasei
DTA81. *Microorganisms* 8 (2020).

130. Mendes, M.C.S. *et al.* Microbiota modification by probiotic supplementation
reduces colitis associated colon cancer in mice. *World J Gastroenterol* 24, 19952008 (2018).

131. Zhang, S.L. *et al.* Pectin supplement significantly enhanced the anti-PD-1
efficacy in tumor-bearing mice humanized with gut microbiota from patients with
colorectal cancer. *Theranostics* **11**, 4155-4170 (2021).

132. Li, Y. *et al.* Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth. *Cell Rep* **30**, 1753-1766 e1756 (2020).

133. Zhu, L.Q. *et al.* Evodiamine inhibits high-fat diet-induced colitis-associated
cancer in mice through regulating the gut microbiota. *J Integr Med* **19**, 56-65 (2021).

134. Terasaki, M. *et al.* Alteration of fecal microbiota by fucoxanthin results in
 prevention of colorectal cancer in AOM/DSS-treated mice. *Carcinogenesis* (2020).

135. Luo, L. et al. The effect of menthol supplement diet on colitis-induced colon

tumorigenesis and intestinal microbiota. *Am J Transl Res* **13**, 38-56 (2021).

136. Liu, X., Wang, L., Jing, N., Jiang, G. & Liu, Z. Biostimulating Gut Microbiome

with Bilberry Anthocyanin Combo to Enhance Anti-PD-L1 Efficiency against Murine
Colon Cancer. *Microorganisms* 8 (2020).

137. Zhang, H., Hui, D., Li, Y., Xiong, G. & Fu, X. Canmei Formula Reduces Colitis-

978 Associated Colorectal Carcinogenesis in Mice by Modulating the Composition of Gut

979 Microbiota. Front Oncol 9, 1149 (2019).

138. Khan, I. *et al.* Mushroom polysaccharides and jiaogulan saponins exert cancer

preventive effects by shaping the gut microbiota and microenvironment in Apc(Min/+)
 mice. *Pharmacol Res* 148, 104448 (2019).

139. Li, S., Fu, C., Zhao, Y. & He, J. Intervention with alpha-Ketoglutarate
Ameliorates Colitis-Related Colorectal Carcinoma via Modulation of the Gut
Microbiome. *Biomed Res Int* 2019, 8020785 (2019).

140. Fernandez, J. *et al.* A Galacto-Oligosaccharides Preparation Derived From
Lactulose Protects Against Colorectal Cancer Development in an Animal Model. *Front Microbiol* 9, 2004 (2018).

141. Mudd, A.M. *et al.* Chemoprevention of Colorectal Cancer by Anthocyanidins
and Mitigation of Metabolic Shifts Induced by Dysbiosis of the Gut Microbiome. *Cancer Prev Res (Phila)* **13**, 41-52 (2020).

992 142. Wu, J.C. *et al.* Polymethoxyflavones prevent benzo[a]pyrene/dextran sodium
993 sulfate-induced colorectal carcinogenesis through modulating xenobiotic metabolism
994 and ameliorate autophagic defect in ICR mice. *Int J Cancer* **142**, 1689-1701 (2018).

143. Wang, X. *et al.* Structural shift of gut microbiota during chemo-preventive
effects of epigallocatechin gallate on colorectal carcinogenesis in mice. *World J Gastroenterol* 23, 8128-8139 (2017).

144. Chou, Y.C. *et al.* Boswellia serrata resin extract alleviates azoxymethane
(AOM)/dextran sodium sulfate (DSS)-induced colon tumorigenesis. *Mol Nutr Food Res* 61 (2017).

1001 145. Fukuda, M. *et al.* Prebiotic treatment reduced preneoplastic lesions through
1002 the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model. *J*1003 *Clin Biochem Nutr* 49, 57-61 (2011).

1004 146. Oh, N.S., Lee, J.Y., Kim, Y.T., Kim, S.H. & Lee, J.H. Cancer-protective effect 1005 of a synbiotic combination between Lactobacillus gasseri 505 and a Cudrania 1006 tricuspidata leaf extract on colitis-associated colorectal cancer. *Gut Microbes* **12**, 1007 1785803 (2020).

1008 147. Rudd, D.A. *et al.* Mapping insoluble indole metabolites in the gastrointestinal 1009 environment of a murine colorectal cancer model using desorption/ionisation on 1010 porous silicon imaging. *Sci Rep* **9**, 12342 (2019).

148. Zhang, J. *et al.* A Functional Food Inhibits Azoxymethane/Dextran Sulfate
Sodium-Induced Inflammatory Colorectal Cancer in Mice. *Onco Targets Ther* 14,
1465-1477 (2021).

1014 149. Piazzi, G. *et al.* A Mediterranean Diet Mix Has Chemopreventive Effects in a

1015 Murine Model of Colorectal Cancer Modulating Apoptosis and the Gut Microbiota.

1016 *Front Oncol* **9**, 140 (2019).

1017 150. Li, F. *et al.* Modulation of colon cancer by nutmeg. *J Proteome Res* 14, 19371018 1946 (2015).

1019 151. Chen, L. *et al.* Chemoprevention of colorectal cancer by black raspberry
1020 anthocyanins involved the modulation of gut microbiota and SFRP2 demethylation.
1021 *Carcinogenesis* **39**, 471-481 (2018).

1022 152. Fernandez, J., Garcia, L., Monte, J., Villar, C.J. & Lombo, F. Functional 1023 Anthocyanin-Rich Sausages Diminish Colorectal Cancer in an Animal Model and 1024 Reduce Pro-Inflammatory Bacteria in the Intestinal Microbiota. *Genes (Basel)* **9** 1025 (2018).

1026 153. Wang, C.Z. *et al.* Role of intestinal microbiome in American ginseng-mediated
1027 colon cancer prevention in high fat diet-fed AOM/DSS mice [corrected]. *Clin Transl*1028 *Oncol* 20, 302-312 (2018).

1029 154. Hu, Y. *et al.* Manipulation of the gut microbiota using resistant starch is 1030 associated with protection against colitis-associated colorectal cancer in rats. 1031 *Carcinogenesis* **37**, 366-375 (2016).

1032 155. Yu, C. *et al.* American ginseng significantly reduced the progression of high-1033 fat-diet-enhanced colon carcinogenesis in Apc (Min/+) mice. *J Ginseng Res* **39**, 230-1034 237 (2015).

1035 156. Gao, Z. *et al.* Probiotics modify human intestinal mucosa-associated 1036 microbiota in patients with colorectal cancer. *Mol Med Rep* **12**, 6119-6127 (2015).

1037 157. Zhang, J.W. *et al.* Preoperative probiotics decrease postoperative infectious 1038 complications of colorectal cancer. *Am J Med Sci* **343**, 199-205 (2012).

1039 158. Aisu, N. *et al.* Impact of perioperative probiotic treatment for surgical site 1040 infections in patients with colorectal cancer. *Exp Ther Med* **10**, 966-972 (2015).

1041 159. Liu, Z. *et al.* Randomised clinical trial: the effects of perioperative probiotic 1042 treatment on barrier function and post-operative infectious complications in colorectal 1043 cancer surgery - a double-blind study. *Aliment Pharmacol Ther* **33**, 50-63 (2011).

1044 160. Gianotti, L. *et al.* A randomized double-blind trial on perioperative 1045 administration of probiotics in colorectal cancer patients. *World J Gastroenterol* **16**, 1046 167-175 (2010).

1047 161. So, W.K.W. *et al.* Effects of a Rice Bran Dietary Intervention on the 1048 Composition of the Intestinal Microbiota of Adults with a High Risk of Colorectal 1049 Cancer: A Pilot Randomised-Controlled Trial. *Nutrients* **13** (2021).

1050 162. Xie, X. *et al.* Effects of prebiotics on immunologic indicators and intestinal
1051 microbiota structure in perioperative colorectal cancer patients. *Nutrition* **61**, 132-142
1052 (2019).

1053 163. Polakowski, C.B., Kato, M., Preti, V.B., Schieferdecker, M.E.M. & Ligocki 1054 Campos, A.C. Impact of the preoperative use of synbiotics in colorectal cancer 1055 patients: A prospective, randomized, double-blind, placebo-controlled study. *Nutrition* 1056 **58**, 40-46 (2019).

1057 164. Hibberd, A.A. *et al.* Intestinal microbiota is altered in patients with colon cancer 1058 and modified by probiotic intervention. *BMJ Open Gastroenterol* **4**, e000145 (2017).

1059 165. Worthley, D.L. *et al.* A human, double-blind, placebo-controlled, crossover trial 1060 of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, 1061 inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. *Am J Clin* 1062 *Nutr* **90**, 578-586 (2009).

1063 166. Brown, D.G., Borresen, E.C., Brown, R.J. & Ryan, E.P. Heat-stabilised rice 1064 bran consumption by colorectal cancer survivors modulates stool metabolite profiles 1065 and metabolic networks: a randomised controlled trial. *Br J Nutr* **117**, 1244-1256 1066 (2017).

1067 167. Nunez-Sanchez, M.A. *et al.* Gene expression changes in colon tissues from 1068 colorectal cancer patients following the intake of an ellagitannin-containing 1069 pomegranate extract: a randomized clinical trial. *J Nutr Biochem* **42**, 126-133 (2017).

1070 168. Nunez-Sanchez, M.A. *et al.* MicroRNAs expression in normal and malignant 1071 colon tissues as biomarkers of colorectal cancer and in response to pomegranate 1072 extracts consumption: Critical issues to discern between modulatory effects and 1073 potential artefacts. *Mol Nutr Food Res* **59**, 1973-1986 (2015).

1074 169. Chen, C.C. *et al.* Oral inoculation of probiotics Lactobacillus acidophilus NCFM 1075 suppresses tumour growth both in segmental orthotopic colon cancer and extra-1076 intestinal tissue. *Br J Nutr* **107**, 1623-1634 (2012).

1077 170. Bellville, J.W., Swanson, G.D., Miyake, T. & Aqleh, K.A. Respiratory 1078 stimulation observed following ethanol ingestion. *West J Med* **124**, 423-425 (1976).

37

1079 171. Shinohara, K., Ohashi, Y., Kawasumi, K., Terada, A. & Fujisawa, T. Effect of 1080 apple intake on fecal microbiota and metabolites in humans. *Anaerobe* **16**, 510-515 1081 (2010).

1082 172. Schwartz, S.E. *et al.* Sustained pectin ingestion: effect on gastric emptying 1083 and glucose tolerance in non-insulin-dependent diabetic patients. *Am J Clin Nutr* **48**, 1084 1413-1417 (1988).

1085173. Annunziata, G. *et al.* Effect of Grape Pomace Polyphenols With or Without1086Pectin on TMAO Serum Levels Assessed by LC/MS-Based Assay: A Preliminary

1087 Clinical Study on Overweight/Obese Subjects. *Front Pharmacol* **10**, 575 (2019).

1088 174. Glinsky, V.V. & Raz, A. Modified citrus pectin anti-metastatic properties: one 1089 bullet, multiple targets. *Carbohydr Res* **344**, 1788-1791 (2009).

1090 175. Warburg, O. On the origin of cancer cells. *Science* **123**, 309-314 (1956).

1091 176. Roediger, W.E. Role of anaerobic bacteria in the metabolic welfare of the 1092 colonic mucosa in man. *Gut* **21**, 793-798 (1980).

1093 177. Khoo, H.E., Azlan, A., Tang, S.T. & Lim, S.M. Anthocyanidins and 1094 anthocyanins: colored pigments as food, pharmaceutical ingredients, and the 1095 potential health benefits. *Food Nutr Res* **61**, 1361779 (2017).

1096 178. Reglero, C. & Reglero, G. Precision Nutrition and Cancer Relapse Prevention:

1097 A Systematic Literature Review. *Nutrients* **11** (2019).

1098 179. Toledo, E. *et al.* Mediterranean Diet and Invasive Breast Cancer Risk Among

1099 Women at High Cardiovascular Risk in the PREDIMED Trial: A Randomized Clinical

1100 Trial. JAMA Intern Med **175**, 1752-1760 (2015).

1101 180. Bamia, C. *et al.* Mediterranean diet and colorectal cancer risk: results from a

1102 European cohort. *Eur J Epidemiol* **28**, 317-328 (2013).

1103 **181**. **(2018)**.

1104 182. Henderson, A.J. *et al.* Chemopreventive properties of dietary rice bran: current
1105 status and future prospects. *Adv Nutr* **3**, 643-653 (2012).

1106

1107

- 1108 1109
- 1110
- 1111
- 1112

1113 1114

1115

1116	
1117 1118	
1119	
1120	
1121 1122	
1123	
1124	
1125 1126	
1127	
1128	
1129 1130	
1131	
1132	
1133	Figure legends
1134	
1135	Figure 1. Flow chart of the search and selection process.
1136	
1137	Figure 2. Distribution of the studies analyzed. a. Preclinical and clinical studies. b
1138	and c. Pre-, pro-, symbiotics and food in b. preclinical and c. clinical studies. d.
1139	Strains used as probiotics in preclinical studies. e. Prebiotics used in preclinical
1140	studies. f. Strains used as probiotics in clinical studies. g. Prebiotics used in clinical
1141	studies. * More than 1 pro- and prebiotic is used in some studies.
1142	
1143	
1144	
1145	
1146	
1147	
1148	
1149	
1150	
1151	
1152	
1153	
1154	

1155			
1156			
1157			
1158			
1159			
1160			
1161			
1162			
1163			
1164			
1165			
1166			

Table 1. Details of the search strategy used.

Field	Key words	Boolean
Field	Key words	Operator
Title	(Cancer* OR carcino* OR tumor* OR onco*)	AND
Title/Abstract	(colon* OR colorect*)	AND
Title/Abstract	(microbi* OR dysbi*)	AND
Title/Abstract	(chemo* OR immuno* OR car-t* OR radium* OR surgery* OR therapy*	AND
Title/Abstract	(nutrition* OR diet* OR food* OR probio* OR prebio* OR symbio*)	NOT
Type of publication	(Biography OR Comment OR Duplicate publication OR Editorial OR Guideline OR Interview OR News OR Personal Narrative OR Published Erratum OR Retracted Publication OR Retraction of Publication OR Meta-Analysis OR Review OR Systematic Review)	

Using words/prefixes with an asterisk opens the search to more results based on plurals and varying suffixes.

1167

Table 2. Summary of the results of the articles analyzed.

Intervention	Type of cancer	Type of study	Impact on microbiota	Mechanism	Effect on the tumor	Ref	Scientific quality				
		1	Preclinical studies			J	,				
	Probiotics										
Probiotic: Akkermansia muciniphila	Subcutane ous, syngeneic model of colon cancer	Female BALB/c mice injected subcutaneousl y with CT26 cells in combination or not with IL-2	↑ diversity and Akkermansia, Allstipes and Lactobacillus	$\label{eq:constraint} \begin{array}{c} \uparrow \mbox{ necrosis, } \downarrow \\ \mbox{ proliferation, } \\ \mbox{ and } \uparrow \mbox{ tumor } \\ \mbox{ apoptosis. } \\ \uparrow \mbox{ CTL and } \downarrow \\ \mbox{ Treg } \\ \mbox{ recruitment. } \uparrow \\ \mbox{ IFN-γ and IL-2 in the tumor } \\ \mbox{ and } \uparrow \mbox{ TNF-α in serum, } \\ \mbox{ together with } \downarrow \\ \mbox{ TGF-β. The } \\ \mbox{ Amuc protein } \\ \mbox{ effects through } \\ \mbox{ TLR2. } \end{array}$	↓ tumor volume and weight and ↑ survival time	115	4				
Probiotic: VSL#3, is composed of: Lactobacillus plantarum, Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacteriu m longum, Bifidobacteriu m infantis and Streptococcus salivarius subsp. Thermophilus.	Gnobiotic model of CRC associated with colitis and inflammati on	129/SvEv deficient in IL10 treated with AOM	↓ <i>Verrucomicrobia</i> and ↑ <i>Proteobacteria</i> in the mucosa. ↓ <i>Bacteroidetes</i> in feces	↓ <i>Clostridium</i> in the mucous membrane	↑ penetrance, invasiveness , histological grade, tumor volume and number of tumors		4				
Inactivated	CRC	Syngeneic	↓ Proteobacteria		\downarrow of tumors	76	3				

probiotic: Lactobacillus acidophilus lysates (Phylum Firmicutes)	associated with colitis	male BALB/C treated with AOM and DSS		\uparrow Th1 lymphocytes (CD3 + CD4 + IFN-γ+) and M1 macrophages (CD11b + F4/80 + CD86+) in mesenteric lymphoid nodules. In combination with anti CTLA-4 \uparrow TCD8+ effector memory (CD44 + CD8 + CD62L+), \downarrow Treg (CD4 + CD25 + Foxp3+) and M2 macrophages (F4/80 + CD206+) in the tumor microenvironm ent. In addition to \uparrow IL-2 in nodules and plasma and plasma IFN-γ	and trend towards ↑ survival in combination with CTLA-4 inhibitors		
Probiotic: Lactobacillus rhamnosus, Lactobacillus plantarum and Pediococcus pentosaceus	Early colon carcinoge nesis	Male Wistar rats treated with DHM	↑ lactic acid bacteria	↓ weight loss, fecal pH, liver transaminases and fecal enzyme normalization	↓ aberrant intestinal crypts, especially with <i>L.</i> <i>rhamnosus</i> .	117	3
Probiotic: Enterococcus faecalis, Bifidobacteriu m longum and Lactobacillus acidophilus (Bifico)	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ Lactobacillus.↓ Desulfovibrio, Mucispirillum, and Odoribacter	$ \begin{tabular}{lllllllllllllllllllllllllllllllllll$	↓ number and volume of tumors	118	3
Probiotic: Akkermansia muciniphila or its specific membrane protein Amuc_1100	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	NR	↑ cytotoxic TCD8 in mesenteric nodules. ↑ TCD8-TNF-α+ and ↓ TCD8- PD-1+. ↓ TCD8 and Ki67 in colon.	↓ malignancy score, tumor formation and area	36	2
Probiotic: Lactobacillus rhamnosus M9	CRC associated with colitis	Male 6- C57BL/6NCrSI c mice treated with AOM and DSS	↑ diversity of the flora and ↑ of Blautia, Akkermansia, Lactobacillus and Bifidobacterium	↓ PCNA, pSTAT3, pAKT.↓ CD68+ and CD163+ in subserosa.	↓ number and size of tumors. ↓ inflammatory and fibrotic score.	119	2
Probiotic: Butyricicoccus pullicaecorum	CRC associated with colitis	male BALB/cByJNar I treated with DHM	NR	↑ SLC5A8 and GPR43	↓ infiltration, anal bleeding, and CEA levels	120	2

Probiotic: Lactobacillus plantarum VD23 Lactobacillus plantarum C28 Lactobacillus plantarum MS18 Lactobacillus salivarius MS3 Lactobacillus salivarius MS6 Lactobacillus salivarius	Early colon carcinoge nesis	Male Wistar rats treated with DHM	NR	∱IL-18	↓ proliferation, volume and total number of tumors. ↑ colon length (non- significant results)	121	2
Probiotic: Lactobacillus bulgaricus	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	NR	↓ IL-6, TNF-α, IL-17, IL-23 and IL-1β and ↑ IFN-γ in healthy and tumor intestinal tissue	↓ mean tumor volume and size. ↓ pathological severity score and ↑ colon length.	122	2
Probiotic: Bifidobacteriu m and Lactobacillus	Subcutane ous, syngeneic model of colon cancer	Female BALB/c mice injected subcutaneousl y with CT26 cells	↑ Alloprebotella, Citrobacter, Prevotellaceae_UC G-001, Roseburia, Thalassospira, Erysipelatoclostridiu m and Lachnospiraceae_U CG-006. ↓ Desulfovibrio, Anaerotruncus, Mucispirillum, Odoribacter. and Escherichia- Shigella. ↑ Bacteroides_chinchil lae and Helicobacter_ Ganmani. ↓ Escherichia coli, Lachnospiraceae bacterium_COE1, Bacteroides vulgatus and Lachnospiraceae bacterium_10-1	NR	No change in tumor volume	123	2
Probiotic: Lactobacillus casei variety rhamnosus (Lcr35)	Subcutane ous, syngeneic model of colon cancer	Male BALB/c mice injected subcutaneousl y with CT26 cells and treated with FOLFOX (5- fluorouracil, leucovorin, and Lactobacillus casei oxaliplatin).	↑ <i>Firmicutes</i> and <i>Bacteroidetes</i>	↓ severe diarrhea and mucositis. ↓ apoptotic cells, NF-κB and BAX. ↓ TNF-α and IL6.	Unchanged	124	2
Probiotic: Faecalibacteri um prausnitzii	Subcutane ous model, colon cancer with cachexia	Male CD2F1 mice injected subcutaneousl y with C26 (I understand this refers to CT26, although it is	NR	Improvement of various parameters related to the intestinal barrier, but not significant	↓ tumor mass, not significant	125	2

		not specified).					
Probiotic: Lactobacillus casei BL23	CRC associated with colitis	C57BL/6 WT females treated with AOM and DSS	↑ Lactobacillus zeae	↓ Ki67. ↑ Bik	↓ tumor volume, number of tumors and histological malignancy	126	2
Probiotic: Lactobacillus reuteri	CRC associated with colitis	Hdc-/- BALB/c male BALB/c treated with AOM and DSS	NR	↓ tumor zone KC, IL22, IL6, TNF-α, IL-1-α. ↓ serum KC, IL22, IL6.↓ CD11b+Gr-1+	↓ number of tumors	127	2
Probiotic: VSL#3, is composed of: Lactobacillus plantarum, Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus paracasei, Lactobacillus paracasei, Lactobacillus baracasei, Lactobacillus bifidobacteriu m breve, Bifidobacteriu m longum, Bifidobacteriu m infantis and Streptococcus salivarius subsp. Thermophilus.	CRC associated with colitis	Male BALB/c WT treated with AOM and DSS with Western diet and metformin.	NR	Metformin + VSL#3 = ↓ Ki67, F4/80	Metformin and metformin+V SL#3 = ↓ number of tumors	128	2
Probiotic: Lactobacillus paracasei DTA81	Early colon carcinoge nesis	male BALB/c WT treated with DHM	↑ Ruminiclostridium and ↑ fecal acetic acid* and short- chain short acids* (*poorly performed comparator groups)	↓ IL-6, IL-17, and PCNA in colonic homogenates	Show no change	129	1
Probiotic: Lactobacillus rhamnosus	Early colon carcinoge nesis	male BALB/c WT treated with DHM	↑ <i>Romboutsia</i> and <i>Turicibacter</i>	↑IL4, IL-10 IL- 6, IL-17, TNF- α, IFN-γ, c- MYC and P-53 in colonic homogenates	Show no change	129	1
Probiotics: Lactobacillus acidophilus, Lactobacillus rhamnosus and Bifidobacteriu m bifidum	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ Lactobacillus, Bifidobacterium, Allobaculum, Clostridium XI, and Clostridium X III	↓ colitis, ↓ circulating levels of RANTES and eotaxin; ↓ p- IKK and TNF-α with ↑ IL-10	↓ incidence and number of tumors	130	1
		·	Prebiotics				
Prebiotic: Fructooligosac charide/inulin	Gnobiotic model of CRC associated with colitis	BALB/C mice (gender undefined) treated with AOM and DSS	NR	↑ histone 3 and ↓ HDAC activity. ↑ levels of Fas and active caspase 3. ↓ of p21, p27 and Ki-67.	↓ histological grade, volume and number of tumors	66	5

Prebiotic: Pectin	Subcutane ous, syngeneic model of colon cancer	Female C57BL/6 WT mice injected with MC38 cells. With humanized microbiota from healthy humans or patients, anti- PD-1 treatment.	↑ diversity, ↑ Lactobacillaceae, Bifidobacteriaceae, Erysipelotrichaceae, Ruminococcaceae, Faecalibacterium, and Holdemania. ↑ percentage Firmicutes/Bacteroid etes. ↑ acetate and butyrate.	↑ TCD4+, TCD8+ and TCD8+IFNγ+ tumor infiltration	↓ tumor volume and size	131	4
Prebiotic: Mucin and inulin	Subcutane ously transplant ed colon cancer (MC-38)	Syngeneic C57BL/6 mice	↑ <i>Clostridium</i> cluster XIVa	↑ of MHC class I and MHC class II expression in CD	Inulin causes↓ tumor volume. No change in tumor volume with Mucin	132	4
Prebiotic: food extract: Evodiamine	CRC associated with colitis	C57BL/6 WT treated with HFD, AOM and DSS	↑ Campylobacter, Bifidobacterium and Lactobacillus.↓ E. faecalis and E. coli	↓ IL-1, IL- 6 and circulating TNF-α and in colonic tissue ↓ p-STAT3 and p-P65	↑ survival, ↓ tumor diameter and percentage weight/lengt h of intestine. ↓ pathological score and proliferation, ↑ apoptosis.	133	3
Prebiotic: Food extract: Fucoxanthin	CRC associated with colitis	ICR WT male treated with AOM and DSS	↑Lachnospiraceae and ↓ <i>Bacteroidales</i> and <i>Rikenellaceae</i>	↑ caspase 3	↓ size and number of colorectal adenomas and total tumors	134	3
Prebiotic: Food extract: Menthol	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ in butyrate- producing bacteria (<i>Allobaculum</i> , <i>Roseburia</i> and <i>Intestinimonas</i>) and fecal ↑ butyrate	$\downarrow expression of \beta-catenin, Ki67, IL-6, TNF-\alpha andMPO. \downarrowinfiltration ofimmune cellsin the spleen,\uparrowIL10 in thedistal colon$	↓ the number of 1- 3 mm adenomas in a dose- dependent manner and damage scales.	135	2
Prebiotic: Chitosan and low molecular weight citrus pectins encapsulating bilberry anthocyanins	Subcutane ously transplant ed colon cancer (MC-38)	Female C57BL/6 mice	↑ <i>Lachnospiraceae</i> (Clostridiales) and diversity	They suggest a ↑ of SCFA and TCD4+ and TCD8+ infiltration of the tumor, but are not significant.	↓ tumor volume in combination with PD-L1 inhibitors.	136	2
Prebiotic: Canmei formula	CRC associated with colitis	C57BL/6 WT females treated with AOM and DSS and HFD	↑ Turicibacter, Bacteroides, Bacteroidaceae, Faecalibaculum, Erysipelatoclostridiu m and Staphylococcus	↓ serum levels of IL-17 and NF-κB	↓ tumor incidence	137	2
Prebiotic: Polysaccharid es from <i>Ganoderma</i> <i>lucidum</i> and saponin from	Prevention of colon cancer of genetic origin	ApcMin+/- male mice	↑ bacteria producing SCFA and ↓ of sulfur-reducing bacteria	Shift from M1 to M2 macrophages. Reversal of expression, E- cadherin/N-	↓ number and size of polyp	138	2

Gynostemma pentaphyllum				cadherin ratio			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				oncogenic signaling.↑ signaling of Gprotein coupled- receptors due to modulation of histone deacetylases, PYY and PPARγ expression.			
Prebiotic α- ketoglutarate	CRC associated with colitis	C57BL/6 WT females treated with AOM and DSS	↑ diversity. ↑ Akkermansia, Butyricicoccus, Clostridium and Ruminocococcus. ↓ Escherichia and Enterococcus.	↓ IL-6, IL-22, TNF-α, and IL- 1β	↓ tumor frequency, size, and stage.	139	2
Prebiotic: Lactulose- derived galacto- oligosaccharid es	CRC associated with colitis	Male <i>Rattus</i> <i>norvegicus</i> F344 rats treated with AOM and DSS	↑ propionate. ↑ diversity of flora, anti-inflammatory: Bifidobacterium, Bacteroidaceae, Prevotellaceae, Acidaminococcaceae, e, Bifidobacteriaceae, Peptococcaceae, Oscillospiraceae and ↓ of pro- inflammatory: Lachnospiraceae, Eubacteriaceae, Acholeplasmatacea e and Firmicutes/Bacteroid etes %.	↑ cecum length	↓ number and volume of polyps	140	2
Prebiotic: Anthocyanidin s wrapped or not in exosomes.	CRC associated with dysbiosis	ApcMin/+ Mice Inoculated with Bacteroides fragilis	NR	↑ in the liver, but not in the tumor, of phase I enzymes CYP1A1 and CYP1B1 and ↓ of phase II enzymes GSTM1 and SULT1	↓ number of tumors	141	1
Prebiotic: polymethoxyfl avones	CRC associated with colitis	ICR WT males treated with benzo[a]pyren e and DSS	↑ Sphingobacteriacea e, Gammaproteobacter ia, Ruminococcaceae and Blautia.↓ Bacilli, Parabacteroides, Lactobacillus Ruminis (without statistical analysis)	<pre>↑ colon size. ↓ hepatic and renal toxicity. ↓ BaP-7,8- dihydrodiol- 9,10-epoxide- DNA binding. ↓ genes for inflammation, metastasis and ↑ antioxidants.</pre>	↓ hyperplasias , adenoma and adenocarcin omas	142	1
Prebiotic: Epigallocatech in gallate (EGCG)	CRC associated with colitis	FVB/N WT female treated with benzo[a]pyren e and DSS	↑ Lactobacillus, Fusobacterium, Ruminococcus, ↓ Bacteroides, Anaerotruncus	NR	↓ volume and number of tumors and pre- cancerous lesions	143	1
Prebiotic: Boswellia	CRC associated	ICR WT male treated with	↑ <i>Clostridiales spp</i> and ↓ <i>Bacteroidales</i>	↓ NF-κB, PCNA. ↑	↓ number of tumors	144	1

<i>serrata</i> resin extract	with colitis	AOM and DSS		colon length			
Prebiotic: Germinated barley extract	CRC associated with colitis	AOM-treated male Fisher 344 rats	NR	↓ TLR4 and COX2	↓ aberrant crypts	145	1
			Symbiotics	·			1
Symbiotic: Clostridium butyricum and prebiotic dextran	Subcutane ous and orthotopic model of colon cancer	CT26luc and ApcMin+/-	↑ Muribaculaceae, Bacteroides, Mucispirillum, Alloprevotella, Lachnospiraceae, and Ruminococcaceae	↑ iso-butyrate, butyrate, iso- valerate, iso- propionate, valerate, iso- hexanoate, and hexanoate, ↓ dysbiosis	↑ effectivenes s of capecitabine and diclofenac, ↓ tumor size of 74% /in combination with diclofenac, while diclofenac, only 11%, abdominal invasion, ↑ apoptosis	96	5
Symbiotic: Lactobacillus gasseri 505 (LG) and leaf extract of <i>Cudrania</i> <i>tricuspidata</i> (CT) in fermented milk called FCT	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ Lactobacillus, Bifidobacterium, and Akkermansia associated with ↑ SCFA and ↓ Staphylococcus	$\begin{array}{l} \downarrow \text{TNF-}\alpha, \text{ IFN-}\\ \gamma, \text{ IL-1}\beta, \text{ IL-6},\\ \text{iNOS and}\\ \text{COX-}2.\uparrow \text{ IL-4}\\ \text{and IL-10.}\uparrow\\ \text{MUC2}, \text{ TFF3}\\ \text{and ZO-1.}\uparrow\\ \text{p53}, \text{p21}, \text{ and}\\ \text{Bax.}\downarrow \text{ Bcl-2}\\ \text{and Bcl-xL.}\downarrow\\ \beta\text{-}\\ \text{Catenin, NF-}\\ \text{\kappaB and}\uparrow \text{ I}\text{ KB-}\alpha \end{array}$	↓ incidence of tumors and dysplasia. ↑ colon length	146	3
			Food				
Western diet, antibiotics and <i>Enterococcus</i> <i>faecalis.</i>	Model of CRC recurrence after surgery	Male BALB/c mice inoculated with CT26 after resection and anastomosis	Western diet = $\uparrow E$. faecalis. Western diet associated with tumors \uparrow Proteus, Akkermansia and Trabulsiella. \downarrow in Bacteroides, Roseburia and Ruminococcus. Inoculation with E. faecalis = \uparrow Proteus, Enterococcus, Trabulsiella Akkermansia and Clostridium and \downarrow Roseburia.	NR	↑ tumor formation with Western diet and <i>E.</i> <i>faecalis.</i> ↑ distant metastasis with Western diet (not significant).	105	4
Food extract: selfish Muricidae: 1. marine extract (NE) 2. metabolite of the extract 6-bromoisatin (6-Br)	CRC genotoxic	AOM-treated male C57BL/6 WT	NR	6-Br =↓ tumor proliferation. NE = ↓ proliferation and ↑ apoptosis in crypts.	6-Br =↓ number of aberrant crypts and tumors. NE = ↓ number of tumors	147	4
Functional food: extract of 55 different foodstuffs mixed	CRC associated with colitis	AOM- and DSS-treated male BALB/c mice	↓ Desulfovibrio and Ruminococcaceae and ↑ from Bacteroides, Ruminiclostridium_6, Holde manella, Clostridium_sensu_	Improved intestinal barrier and body weight maintenance. ↓ IL-6 and TNF-α.↑ in	↓ number and size of tumors. ↑ survival	148	3

			stricto_1, Allobaculum and Parasutterella. ↓ of deuteroporphyrin IX, citrulline, and diferuloylputrescine, and ↑-acid acetic, ascorbic, palmitic, quinic, ursocholic, branched amino acids, rosmaridiphenol and scillirosidine	the proportion of total T cells, CD3+CD4+, CD3+CD8+, and IFN-γ- producing CD4+ T cells.			
Diet: - low fat (LFD) - high fat (HFD) - a mixture of one of them with Mediterranean (MD). This being a mixture of ω-3 polyunsaturate d fatty acids (PUFA), eicosapentano ic acid and polyphenols.	CRC genotoxic	A/J WT male treated with AOM	MD improves dysbiosis with an HFD, but worsens it with an LFD.	MD ↑ apoptosis in HFD, and especially in LFD. MD ↑ eicosapentano ic acid (EPA), especially in LFD.	MD↓ incidence in HFD, but especially in LFD	149	3
Food extract: Nutmeg	Prevention of colon cancer of genetic origin	C57BL/6J WT and ApcMin+/- Male Mice	NR	 ↓ in urine of cresol sulphate and glucuronide, indoxyl sulphate and phenyl sulphate.↓ colon and liver L6.↓ ALT and amylase.↑ LPE 18:0, LPC 18:0, azelaic acid, sebacic acid, sebacic acid, palmitolcarniti ne and oleocarnitine. ↑ lipid metabolism gene expression in the colon and liver 	↓ tumor volume and number of tumors	150	3
Food extract: Anthocyanin extract from blackberries.	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	 ↑ Eubacterium rectale, Faecalibacterium prausnitzii and Lactobacillus. ↓ Desulfovibrio and Enterococcus spp. 	$\begin{tabular}{l} &\uparrow SFRP2 \\ triggers the \downarrow \\ of DNMT1 and \\ p-STAT3. In \\ addition to \downarrow \\ IL-1$, IL-6, II- \\ 10, COX-2 \\ and TNF-α. \end{tabular}$	↓ number of tumors	151	2
Food extract: Anthocyanins extracted from strawberries and blackberries	CRC associated with colitis	Male <i>Rattus</i> norvegicus F344 rats treated with AOM and DSS	↓ Bilophila wadsworthia	Improved plasma reducing capacity	↓ number of tumors	152	2
Food extract: American	CRC associated	A/J male treated with	Improving dysbiosis	NR	↓ number of tumors and	153	2

Ginseng	with colitis	AOM and DSS			histological		
Food extract and prebiotic: Green tea extract (EGCG) and resistant starch	CRC associated with colitis	and HFD Male Sprague- Dawley rats treated with AOM and DSS	↑ Parabacteroides, Barnesiella, Ruminococcus, Marvinbryantia and Bifidobacterium. ↑ acetate, butyrate and propionate.	↑ GPR43. ↓ COX-2, NF- kB, TNF-α and IL-1β.	malignancy Resistant starch = ↓ number of tumors and adenocarcin oma formation	154	2
Food extract: American Ginseng	Prevention of colon cancer of genetic origin with a Western diet	Male ApcMin+/- mice on high- fat diet	NR	↓ IL-1α, IL-1β, IL6, TNF-α, G- CSF and GM- CSF	↓ tumor volume and number of tumors	155	2
			Clinical studies				
			Probiotics				
Probiotic: Bifidobacteriu m longum, Lactobacillus acidophilus and Enterococcus faecalis	Patients with CRC who have previously undergone radical surgery and who are about to undergo further surgery.	Randomized clinical trial Peri-surgery placebo (n=11), probiotic (n=11). Healthy control patients (n=11).	↑ Enterococcus and ↓ Peptostreptococcus, Comamonas, Fusobacterium	NR	NR	156	2
Probiotic: Bifidobacteriu m longum, Lactobacillus acidophilus and Enterococcus faecalis	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Randomized clinical study Placebo (n=30), preoperative probiotic (n=30)	↑ preoperative percentage Bifidobacterium/E. coli	↑ IgG and sIga in serum.↓ endotoxins, D- lactic acid, IL- 6 and CRP	↓ incidence of post- surgery infections	- 157 -	2
Probiotic: Enterococcus faecalis T110, Clostridium butyricum TO- A and Bacillus mesentericus	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Clinical study Control (n=81), Probiotic (n=75)	NR	↓ incisional infections and reduced acute inflammation after surgery	NR	158	2
Probiotic: Lactobacillus plantarum, <i>Lactobacillus</i> <i>acidophilus</i> and <i>Bifidobacteriu</i> <i>m longum</i>	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Randomized double-blind clinical study. Placebo (n=50), perioperative probiotic (n=50).	↑ diversity. ↑ Bifidobacterium and Lactobacilli. ↓ Enterobacteriaceae, Pseudomonas and Candida	↑ claudin1, JAM1 and occludin	NR	159	2
Probiotic: Bifidobacteriu m longum (BB536) and Lactobacillus johnsonii (La1)	CRC patients whose tumor could be removed	Randomized double-blind clinical study. Placebo (n=10), probiotic	La1 = ↑ La1 in mucosa and feces. ↓ Enterobacteriaceae	↑ CD3, CD4, CD8 and naive and memory lymphocytes. ↓ CD83-123 markers,	NR	160	2

	by surgery and who are scheduled for surgery	mixture at a dose of ¹⁰⁷ (n=11) and probiotic mixture at a dose of 109 (n=11). Peri- surgery treatment		CD83-HLADR, and CD83-11c						
Probiotic: Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacteriu m lactis, Bifidobacteriu m bifidobacteriu m bifidobacteriu m birdum, Bifidobacteriu m breve, Streptococcus thermophilus	Stage III colorectal adenocarc inoma	Randomized clinical study of 78 patients with colorectal carcinoma with surgery	NR	NR	↓ number of complication s associated with surgery	74	1			
	I	I	Prebiotics	I		,	,			
Prebiotic: food extract: evodiamine	CRC patients	CRC patients undergoing colonoscopies vs. healthy patients without any colorectal disease	↑ <i>E. faecalis</i> and <i>E.</i> coli↓ Campylobacter, Bifidobacterium and Lactobacillus in CRC. ↑ Endotoxin and D-lactic acid in CRC.	↑ pSTAT3 in cancerous vs. peritumor biopsies	↓ proliferation, p-STAT3 and p-P65 after incubation with evodiamine in colon cancer cell lines HCT- 116 and SW-480	133	3			
Prebiotic: Rice bran	Patients at high risk of developing CRC	Randomized, double-blind, placebo- controlled trial (placebo = 19, treatment = 20). Placebo = rice powder, rice bran treatment. 30 g every 24h, for 24 weeks.	↑ Firmicutes and Lactobacillus	NR	NR	161	3			
Prebiotic: fructo- oligosaccharid es, xylooligosacch arides, polydextrose, and resistant dextrin	CRC patients requiring radical surgery (peri- surgery: pre- and post- surgery are analyzed).	Randomized double-blind clinical study with 140 CRC patients (control = 70; prebiotics = 70)	Pre-surgery = ↑ Bifidobacterium and Enterococus, ↓ Bacteroides. Post-surgery = ↑ Bifidobacterium and Escherichia- Shigella, ↓ Enterococcus	Pre-surgery = ↑ IgG, IgM and transferrin. Post-surgery = ↑ IgG, TCD3+CD8+ (cytotoxic/sup pressive T Iymphocytes) and CD19+ (B Iymphocytes).	NR	162	2			
Symbiotics										
Symbiotic: Maltodextrin as placebo	CRC patients to be treated	Prospective, double-blind, randomized,	NR	↓ plasma IL6 and CRP levels. ↓ post-	3 deaths in the control group and	163	2			

and treatment with Simbioflora® (6g fructooligosac charide, plus <i>Lactobacillus</i> <i>acidophilus</i> <i>NCFM</i> , <i>Lactobacillus</i> <i>rhamnosus</i> <i>HN001</i> , <i>Lactobacillus</i> <i>casei LPC-37</i> and <i>Bifidobacteriu</i> <i>m lactis</i> <i>HN019</i>).	with surgery. Stages I-III	placebo- controlled clinical study (placebo; n = 36. Treatment; n = 37).		surgery infections, antibiotic use and hospital stay.	none in the treatment group.		
Symbiotic: Bifidobacteriu m lactis BI-04, Lactobacillus acidophilus NCFM and inulin	Stage I-III CRCs undergoin g surgery	Clinical trial 21 healthy controls (colonoscopy), 15 CRC patients (8 non- intervention, 7 probiotic)	↑ Firmicutes, Clostridiales spp and Faecalibacterium	NR	NR	164	1
			Pre-, pro- and symbic	otic			
Prebiotic (resistant starch) probiotic (<i>Bifidobacteriu</i> <i>m lactis</i>) or combination of both (symbiotic)	Study in healthy subjects for CRC prevention	Randomized double-blind clinical study with crossover treatments. Healthy subjects, n = 17, for 16 weeks, 4 weeks per arm (placebo, prebiotic, probiotic and symbiotic).	Symbiotic = ↑ <i>Lachnospiraceae</i> spp.	No changes in fecal ammonium, SCFA or circulating cytokines. No epithelial changes.	NR	165	3
	1		Food	1			1
Food extract: Rice bran	CRC patients who have undergone surgery.	Randomized clinical study (control; n = 10. 30g/day rice bran; n = 9)	NR	↑ carbohydrate, lipid, amino acid, cofactor and vitamin metabolism	NR	166	2
Food extract: Pomegranate extract with high ellagitannin content	CRC patients whose tumor could be removed by surgery	Randomized clinical study. Control (n=10), PE (n=35)	NR	↓ CD44 and CTNNB1 in adjacent healthy tissue and tumor. ↓ CDKN1A, EGFR and TYMS in tumor.	NR	167	2
Food extract: Pomegranate extract with high ellagitannin content	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Randomized double-blind clinical study Control (n=11), pomegranate extract #1 (n=19) and #2 (n=16)	NR	Modulation of miRNAs	NR	168	2

Increase/activation has been indicated as (†) and reduction/inhibition as (↓). NR - Not reported. Ref = References



